lumefantrine profile

Lumefantrine: A fluorene derivative that is used in combination with ARTEMETHER for the treatment of MALARIA (see ARTEMETHER-LUMEFANTRINE DRUG COMBINATION). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lumefantrine : A member of the class of fluorenes that is 9-(p-chlorobenzylidene)-9H-fluorene which is substitutec by chlorine at positions 2 and 7, and by a 2-(dibutylamino)-1-hydroxyethyl group at position 4. An antimalarial drug used in combination with artemether for the treatment of multi-drug resistant strains of falciparum malaria. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	6437380
CHEMBL ID	38827
CHEBI ID	156095
SCHEMBL ID	127331
MeSH ID	M0267388

Synonym
AC-4542
lumefantrine (jan/usp/inn)
D03821
82186-77-4
lumefantrine
9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-alpha-((dibutylamino)methyl)-, (z)-
dl-benflumelol
(+-)-2,7-dichloro-9-((z)-p-chlorobenzylidene)-alpha((dibutylamino)methyl)fluorene-4-methanol
benflumetol
(+-)-2,7-dichloro-9-((z)-p-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol
c30h32cl3no
NCGC00167490-01
cpg-56695
benflumelol
lumefantrinum
gnf-pf-1971 ,
CHEMBL38827
(+/-)-2,7-dichloro-9-((z)-p-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol
DB06708
chebi:156095 ,
2-dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9h-fluoren-4-yl]-ethanol
2-dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(z)-ylidene]-9h-fluoren-4-yl}-ethanol
2-(dibutylamino)-1-[(9z)-2,7-dichloro-9-(4-chlorobenzylidene)-9h-fluoren-4-yl]ethanol
2-(dibutylamino)-1-[(9z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol
HMS3260F22
dtxsid3046663 ,
cas-82186-77-4
dtxcid1026663
tox21_112491
AKOS015918181
S3746
2-(dibutylamino)-1-[(9z)-2,7-dichloro-9-[(4-chlorophenyl)methylene]fluoren-4-yl]ethanol
f38r0jr742 ,
unii-f38r0jr742
lumefantrine [usan:inn:ban]
(z)-2-(dibutylamino)-1-(2,7-dichloro-9-(4-chlorobenzylidene)-9h-fluoren-4-yl)ethanol
MLS003899226
smr002543514
STL373579
coartem component lumefantrine
2-dibutylamino-1-(2,7-dichloro-9-(1-(4-chlorophenyl)meth-(z)-ylidene)-9h-fluoren-4-yl)ethanol
lumefantrine [usan]
lumefantrine [usp monograph]
lumefantrine [orange book]
lumefantrine [hsdb]
lumefantrine [usp-rs]
lumefantrine [mi]
lumefantrine [mart.]
lumefantrine [inn]
lumefantrine [who-ip]
lumefantrine [who-dd]
9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-.alpha.-((dibutylamino)methyl)-, (z)-
lumefantrine [vandf]
lumefantrine component of coartem
120583-69-9
lumefantrine [jan]
lumefantrinum [who-ip latin]
(+/-)-2,7-dichloro-9-((z)-p-chlorobenzylidene)-.alpha.((dibutylamino)methyl)fluorene-4-methanol
CCG-221574
SCHEMBL127331
BBL030364
2-(dibutylamino)-1-[(9z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]-9h-fluoren-4-yl]ethan-1-ol
NCGC00167490-03
tox21_112491_1
HS-0098
tox21_500270
CS-5130
NCGC00260955-01
HY-B0803
120583-71-3
ZUV4B00D9P ,
9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-.alpha.-((dibutylamino)methyl)-, (9z)-(-)-
d-benflumelol
lumefantrine, (+)-
9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-.alpha.-((dibutylamino)methyl)-, (9z)-(+)-
9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-.alpha.-((dibutylamino)methyl)-, (z)-(+)-
01NP22J3SV ,
120583-70-2
l-benflumelol
lumefantrine, (-)-
9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-.alpha.-((dibutylamino)methyl)-, (z)-(-)-
(9z)-2,7-dichloro-9-[(4-chlorophenyl)methylene]-alpha-[(dibutylamino)methyl]-9h-fluoren-4-methanol
L0256
mfcd05662268
lumefruntrine
(9z)-2,7-dichloro-9-[(4-chlorophenyl)methylene]-alpha-[(dibutylamino)methyl]-9h-fluorene-4-methanol
lumefantrine, united states pharmacopeia (usp) reference standard
(1rs)-2-(dibutylamino)-1-[(z)-2,7-dichloro-9-(4-chlorobenzylidene)-9h-fluoren-4-yl]ethanol
unii-01np22j3sv
9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-alpha-((dibutylamino)methyl)-, (z)-(-)-
unii-zuv4b00d9p
9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-alpha-((dibutylamino)methyl)-, (9z)-(+)-
9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-alpha-((dibutylamino)methyl)-, (9z)-(-)-
9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-alpha-((dibutylamino)methyl)-, (z)-(+)-
(z)-2-(dibutylamino)-1-(2,7-dichloro-9-(4-chlorobenzylidene)-9h-fluoren-4-yl)ethan-1-ol
Q904464
AMY22191
gtpl9969
NCGC00167490-05
benflumetol, cpg-56695
9h-fluorene-4-methanol, 2,7-dichloro-9-[(4-chlorophenyl)methylene]-?-[(dibutylamino)methyl]-, (9z)- (9ci); 9h-fluorene-4-methanol, 2,7-dichloro-9-[(4-chlorophenyl)methylene]-?-[(dibutylamino)methyl]-, (z)-; benflumelol; benflumetol; lumefantrine; dl-benfl
lumefantrine for system suitability
CS-0368446
EN300-781170

Excerpt	Reference	Relevance
"Lumefantrine (LFN) is a chiral antimalarial drug. "	( Enantioselective in vitro ADME, absolute oral bioavailability, and pharmacokinetics of (-)-lumefantrine and (+)-lumefantrine in mice. Bestha, RM; Dixit, A; Gabani, BB; Kiran, V; Mullangi, R; Narayanan, B; Srinivas, NR, 2021)	2.28
"Lumefantrine is a long-acting antimalarial drug with an elimination half-life of over 3 days and protein binding of 99 percent. "	( Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients. Aweeka, FT; Forsman, C; Huang, L; Kajubi, R; Marzan, F; Mwebaza, N; Parikh, S, 2018)	2.24
"Lumefantrine (LF) is an aryl-amino alcohol antimalarial drug used in artemisinin-based combination therapies against malaria worldwide. "	( Genotoxic effects of the antimalarial drug lumefantrine in human lymphocytes in vitro and computational prediction of the mechanism associated with its interaction with DNA. Bahia, Mde O; Bassi-Branco, CL; Batista Júnior, J; de Lucca, RM; Fontes, CJ, 2015)	2.12
"Lumefantrine (benflumetol) is a fluorene derivative belonging to the aryl amino alcohol class of anti-malarial drugs and is commercially available in fixed combination products with β-artemether. "	( Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-malarial drug lumefantrine. Baert, B; Burvenich, C; De Spiegeleer, B; Duchateau, L; Jansen, FH; Suleman, S; Van Dorpe, S; Vangheluwe, E; Verbeken, M, 2011)	2.04
"Lumefantrine (LMF) is an antimalarial drug that exhibits poor oral bioavailability, owing to its poor aqueous solubility. "	( Enhanced antimalarial activity of lumefantrine nanopowder prepared by wet-milling DYNO MILL technique. Ahmad, FJ; Anwar, M; Gahoi, S; Jain, GK; Khar, RK; Pandey, SK; Singhal, M; Tripathi, R; Warsi, MH, 2012)	2.1

Excerpt	Reference	Relevance
"Lumefantrine has a melting point of 128-131 degrees C. "	( Experimental determination of the physicochemical properties of lumefantrine. Adegoke, AO; Babalola, CP; Kotila, OA; Olaniyi, OO, 2013)	2.07
"Lumefantrine has a melting point of 128-131 degrees C. "	( Experimental determination of the physicochemical properties of lumefantrine. Adegoke, AO; Babalola, CP; Kotila, OA; Olaniyi, OO, 2013)	2.07
"Lumefantrine has been reported to be mainly bio-transformed by cytochrome P450 isozyme 3A4 to desbutyl-lumefantrine (DLF) in human liver microsomes. "	( Gender differences in pharmacokinetics of lumefantrine and its metabolite desbutyl-lumefantrine in rats. Jain, GK; Singh, SP, 2012)	2.09

Excerpt	Reference	Relevance
" There were no major adverse events with either drug."	( Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years. Abdulla, S; Beck, HP; Gathmann, I; Hatz, C; Kibatala, P; Mull, R; Royce, C; Schellenberg, D; Tanner, M, 1998)	0.3
" The most commonly reported and possibly related adverse effects following A-L therapy involved the gastro-intestinal (abdominal pain, anorexia, nausea, vomiting, diarrhoea) and central nervous (headache, dizziness) systems."	( An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Alteri, E; Bakshi, R; Gathmann, I; Hermeling-Fritz, I, )	0.37
"Proportion of treatment success and adverse drug effects that required discontinuation of treatment and/or follow-up."	( Safety and efficacy of artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Ethiopia. Argaw, D; Babaniyi, O; Jima, D; Kebede, A; Medhin, A; Tesfaye, G, 2005)	0.61
"8) and no adverse effects or complaints related to the drug that required discontinuation of treatment or withdrawal from follow-up was reported."	( Safety and efficacy of artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Ethiopia. Argaw, D; Babaniyi, O; Jima, D; Kebede, A; Medhin, A; Tesfaye, G, 2005)	0.61
"1%) clinical and parasitological cure for the treatment of uncomplicated falciparum malaria with no reports of adverse reaction that required withdrawal of treatment or discontinuation of follow-up."	( Safety and efficacy of artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Ethiopia. Argaw, D; Babaniyi, O; Jima, D; Kebede, A; Medhin, A; Tesfaye, G, 2005)	0.61
" The main finding of this analysis is that the six-dose regimen of coartemether is safe and more efficacious than the four-dose regimen in children."	( Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Andriano, K; De Palacios, PI; Falade, C; Hunt, P; Karbwang, J; Makanga, M; Mueller, EA; Premji, Z, 2006)	0.58
"0%) adverse events in 849 patients assigned to pyronaridine-artesunate and 241 (57."	( Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Bedu-Addo, G; Bhatt, KM; Borghini-Fuhrer, I; Bustos, DG; Duparc, S; Fleckenstein, L; Gaye, O; Kayentao, K; Sesay, SS; Shin, CS; Thompson, R; Tjitra, E; Tshefu, AK, 2010)	0.57
"The main objectives of the CEM programme were to proactively determine the adverse event (AE) profile of artesunate/amodiaquine (AA) and artemether/lumefantrine (AL) in real-life settings and to find out the factors predisposing to AEs."	( Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study. Adesina, O; Bassi, PU; Coulter, D; Isah, A; Jalo, I; Kalat, M; Nwoasu, SC; Nyong, EE; Osakwe, AI; Osungwu, F; Pal, S; Suku, C; Ugochukwu, C; Wallberg, M; Wammanda, RD, 2013)	0.59
" Most adverse events occurred from day 1 and peaked by day 2 and 3 of medication with the mean duration of events being 3 days."	( Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study. Adesina, O; Bassi, PU; Coulter, D; Isah, A; Jalo, I; Kalat, M; Nwoasu, SC; Nyong, EE; Osakwe, AI; Osungwu, F; Pal, S; Suku, C; Ugochukwu, C; Wallberg, M; Wammanda, RD, 2013)	0.39
"In conclusion, this pilot CEM programme suggests that adverse events with ACTs were common."	( Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study. Adesina, O; Bassi, PU; Coulter, D; Isah, A; Jalo, I; Kalat, M; Nwoasu, SC; Nyong, EE; Osakwe, AI; Osungwu, F; Pal, S; Suku, C; Ugochukwu, C; Wallberg, M; Wammanda, RD, 2013)	0.39
" The primary end point was parasitological cure on day 28 while the secondary end points included: improvement in haemoglobin levels and occurrence, and severity of adverse events."	( Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania. Buza, J; Ishengoma, DS; Lemnge, MM; Mandara, CI; Shahada, F; Shayo, A, 2014)	0.66
" Reported adverse events included cough (49."	( Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania. Buza, J; Ishengoma, DS; Lemnge, MM; Mandara, CI; Shahada, F; Shayo, A, 2014)	0.66
" Adverse events though common were similar between treatment arms and mostly related to the disease."	( Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children. Afizi, K; Fredrick, M; Kamya, MR; Lameyre, V; Lukwago, R; Talisuna, AO; Yeka, A, 2014)	0.63
"Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive individuals."	( Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Abebe, Y; Billingsley, PF; Chakravarty, S; Diallo, H; Ding, K; Dolo, A; Doumbo, O; Duffy, PE; Fay, MP; Gabriel, EE; Guindo, MA; Gunasekera, A; Healy, SA; Hoffman, SL; James, ER; Kamate, B; Katile, A; Li, M; Manoj, A; Murshedkar, T; Niangaly, A; Niaré, K; Nutman, TB; O'Connell, EM; Omaswa, F; Richie, TL; Ruben, AJ; Samake, Y; Sim, BKL; Sissoko, K; Sissoko, MS; Thera, I; Walther, M; Wong-Madden, S; Zaidi, I; Zeguime, A, 2017)	0.46
" We detected no significant differences in local or systemic adverse events or laboratory abnormalities between the PfSPZ Vaccine and placebo groups, and only grade 1 (mild) local or systemic adverse events occurred in both groups."	( Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Abebe, Y; Billingsley, PF; Chakravarty, S; Diallo, H; Ding, K; Dolo, A; Doumbo, O; Duffy, PE; Fay, MP; Gabriel, EE; Guindo, MA; Gunasekera, A; Healy, SA; Hoffman, SL; James, ER; Kamate, B; Katile, A; Li, M; Manoj, A; Murshedkar, T; Niangaly, A; Niaré, K; Nutman, TB; O'Connell, EM; Omaswa, F; Richie, TL; Ruben, AJ; Samake, Y; Sim, BKL; Sissoko, K; Sissoko, MS; Thera, I; Walther, M; Wong-Madden, S; Zaidi, I; Zeguime, A, 2017)	0.46
" Day 7 lumefantrine concentrations and the number and nature of adverse events were similar between study arms; only one serious adverse event occurred (renal impairment in the no primaquine arm)."	( Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial. Allen, E; Barnes, KI; Frean, J; Mabuza, A; Malatje, G; Raman, J; Swanepoel, H; Wiesner, L; Workman, L, 2019)	0.97
"0%) patients experienced at least one drug-related adverse event (AE)."	( Safety and tolerability of artesunate-amodiaquine, artemether-lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo. Fungula, B; Inocencio da Luz, R; Kalabuanga, M; Lula Ntamba, Y; Lutumba, P; Muhindo Mavoko, H; Ntamabyaliro Nsengi, PM; Tona Lutete, G; Van Geertruyden, JP, 2019)	0.75

Excerpt	Reference	Relevance
"To investigate the pharmacokinetic and pharmacodynamic properties of artemether and benflumetol in a fixed combination tablet (CGP 56697) and to offer an explanation for the lower than expected cure rate in a Thai clinical trial."	( Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Ezzet, F; Karbwang, J; Mull, R, 1998)	0.3
" Parasite clearance time and 28 day cure rate were correlated with the derived pharmacokinetic parameters."	( Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Ezzet, F; Karbwang, J; Mull, R, 1998)	0.3
"Using a population-based approach it was confirmed that the pharmacokinetic and pharmacodynamic properties of benflumetol and artemether differ markedly."	( Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Ezzet, F; Karbwang, J; Mull, R, 1998)	0.3
" The pharmacokinetics of benflumetol were highly variable, with coefficients of variation in pharmacokinetic parameters ranging from 14."	( Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria. Farkad, E; Karbwang, J; Mull, R; Na-Bangchang, K; Tasanor, U; Thanavibul, A, 1999)	0.3
"The objective of this study was to conduct a prospective population pharmacokinetic and pharmacodynamic evaluation of lumefantrine during blinded comparisons of artemether-lumefantrine treatment regimens in uncomplicated multidrug-resistant falciparum malaria."	( Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Ezzet, F; Looareesuwan, S; Nosten, F; van Vugt, M; White, NJ, 2000)	0.78
"To evaluate whether the potent CYP3A4 inhibitor ketoconazole has any influence on the pharmacokinetic and electrocardiographic parameters of the antimalarial co-artemether (artemether-lumefantrine) in healthy subjects."	( Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Carpenter, P; Lefèvre, G; McClean, M; Schmidli, H; Souppart, C; Stypinski, D, 2002)	0.74
"A six-dose antimalarial regimen of artemether-lumefantrine (A/L) may soon become one of the most widely used drug combination in Africa, despite possible constraints with adherence and poor absorption due to inadequate nutrition, and a lack of pharmacokinetic and effectiveness data."	( Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Babigumira, J; Bajunirwe, F; Biraro, S; Checchi, F; Ferradini, L; Fogg, C; Grandesso, F; Guthmann, JP; Kigozi, I; Kiguli, J; Kyomuhendo, J; Piola, P; Ruzagira, E; Taylor, WR, 2006)	0.82
"To determine the pharmacokinetic properties of artemether and lumefantrine (AL) in pregnant women with recrudescent uncomplicated multi-drug resistant falciparum malaria."	( The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Ashley, EA; La, Y; Lindegardh, N; McGready, R; Nosten, F; Singhasivanon, P; Stepniewska, K; White, NJ, 2006)	0.84
" Serial blood samples were taken over a 7-day period, and pharmacokinetic parameters were estimated."	( The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Ashley, EA; La, Y; Lindegardh, N; McGready, R; Nosten, F; Singhasivanon, P; Stepniewska, K; White, NJ, 2006)	0.6
"Lumefantrine pharmacokinetic profiles were obtained for 36 patients."	( Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Annerberg, A; Ashley, EA; Brockman, A; Hla, G; Hutagalung, R; Lindegårdh, N; McGready, R; Nosten, F; Proux, S; Singhasivanon, P; Singtoroj, T; Stepniewska, K; White, NJ; Wilahphaingern, J, 2007)	2.06
" The method was successfully applied for the pharmacokinetic study in rats."	( Determination of lumefantrine in rat plasma by liquid-liquid extraction using LC-MS/MS with electrospray ionization: assay development, validation and application to a pharmacokinetic study. Jain, GK; Singh, SP, 2009)	0.69
" For artemether, trends toward Cmax and AUC decreases (Cmax 14."	( Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. Aweeka, FT; Charlebois, E; Dorsey, G; German, P; Hanpithakpong, W; Havlir, D; Lawrence, J; Lindegardh, N; Parikh, S; Rosenthal, PJ, 2009)	0.59
" The objective of this study was to determine the population pharmacokinetic properties of lumefantrine in pregnant women with uncomplicated multidrug-resistant Plasmodium falciparum malaria on the northwestern border of Thailand."	( Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Annerberg, A; Ashley, EA; Day, NP; Kamanikom, B; Lindegardh, N; McGready, R; Nosten, F; Pimanpanarak, M; Singhasivanon, P; Stepniewska, K; Tarning, J; White, NJ, 2009)	0.86
" Pharmacokinetic (PK) data informing the optimum dosing of these drug regimens is limited, especially in children."	( Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Annerberg, A; Aweeka, F; Clark, TD; Dorsey, G; Drysdale, T; German, P; Kalyango, JN; Kamya, MR; Lindegardh, N; McGee, B; Mwesigwa, J; Parikh, S; Rosenthal, PJ, 2010)	0.65
" The validated method was successfully applied to determine the plasma concentrations of artemether and lumefantrine in healthy volunteers, in a one-dose pharmacokinetic study, over the course of 11 days."	( Liquid chromatography-tandem mass spectrometry for the simultaneous quantitation of artemether and lumefantrine in human plasma: application for a pharmacokinetic study. Bellorio, KB; César, IC; Chellini, PR; de Abreu, FC; Moreira, JM; Pianetti, GA; Ribeiro, JA; Teixeira, Lde S, 2011)	0.8
"The pharmacodynamic interaction between lumefantrine and monodesbutyl-benflumetol has been investigated in 44 fresh isolates of patients with a Plasmodium falciparum infection from the region of Mae Sot (Thailand)."	( Pharmacodynamic interaction between lumefantrine and desbutyl-benflumetol in Plasmodium falciparum in vitro. Congpuong, K; Leeb, A; Satimai, W; Wernsdorfer, G; Wernsdorfer, WH; Wiedermann, U, 2010)	0.9
"The pharmacokinetic and pharmacodynamic properties of a new pediatric formulation of artemether-lumefantrine, dispersible tablet, were determined within the context of a multicenter, randomized, parallel-group study."	( Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. Abdulla, S; Bassat, Q; Borrmann, S; Djimdé, AA; Lefèvre, G; Lyimo, J; Mandomando, I; Tekete, M, 2011)	0.8
"There are sparse published data relating to the pharmacokinetic properties of artemether, lumefantrine, and their active metabolites in children, especially desbutyl-lumefantrine."	( Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. Davis, TM; Griffin, S; Ilett, KF; Kose, K; Mueller, I; Page-Sharp, M; Salman, S; Siba, PM, 2011)	0.85
" Identified articles were included in the review if the study had at least one group that reported at least one pharmacokinetic parameter of interest in pregnant women."	( Pharmacokinetics of antimalarials in pregnancy: a systematic review. Ensom, MH; Wilby, KJ, 2011)	0.37
"The pharmacokinetic parameters of lumefantrine and its metabolite desbutyl-lumefantrine were successfully determined in rats for the first time."	( Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats. Jain, GK; Nafis, A; Puri, SK; Raju, KS; Singh, SP, 2011)	0.86
" Pregnancy has been reported to alter the pharmacokinetic properties of many anti-malarial drugs."	( Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Day, NP; Dhorda, M; Guerin, PJ; Kloprogge, F; Lindegardh, N; Muwanga, S; Nosten, F; Nuengchamnong, N; Piola, P; Tarning, J; Turyakira, E; White, NJ, 2012)	0.38
" A simultaneous drug-metabolite population pharmacokinetic model for artemether and dihydroartemisinin was developed taking into account different disposition, absorption, error and covariate models."	( Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Day, NP; Dhorda, M; Guerin, PJ; Kloprogge, F; Lindegardh, N; Muwanga, S; Nosten, F; Nuengchamnong, N; Piola, P; Tarning, J; Turyakira, E; White, NJ, 2012)	0.38
" The objective was to investigate pharmacokinetic interactions between darunavir/ritonavir or etravirine and arthemether/lumefrantrine."	( Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial. DeMasi, R; Kakuda, TN; Mohammed, P; van Delft, Y, 2013)	0.61
"Pregnancy alters the pharmacokinetic properties of many drugs used in the treatment of malaria, usually resulting in lower drug exposures."	( Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda. Dhorda, M; Guerin, PJ; Jullien, V; Kloprogge, F; Nosten, F; Piola, P; Tarning, J; White, NJ, 2013)	0.63
" The effect of EFV and/or NVP on lumefantrine pharmacokinetic profile among HIV-malaria co-infected patients on ART and treated with AL was investigated."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.91
" Pharmacokinetic analysis of lumefantrine was done using non-linear mixed effect modelling."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.92
"Of the evaluated models, a two-compartment pharmacokinetic model with first order absorption and lag-time described well lumefantrine plasma concentrations time profile."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.84
" A simultaneous pharmacokinetic drug-metabolite model was developed based on dense venous and sparse capillary lumefantrine and desbutyl-lumefantrine plasma samples from 116 pregnant patients on the Thailand-Myanmar border."	( Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border. Blessborn, D; Day, NP; Hanpithakpong, W; Kloprogge, F; McGready, R; Nosten, F; Tarning, J; White, NJ, 2015)	2.07
"The pharmacokinetic compatibility of short-acting CDRI candidate antimalarial trioxane derivative, 99-411, was tested with long-acting prescription antimalarials, lumefantrine and piperaquine."	( Assessment of pharmacokinetic compatibility of short acting CDRI candidate trioxane derivative, 99-411, with long acting prescription antimalarials, lumefantrine and piperaquine. Raju, KS; Singh, SP; Taneja, I; Wahajuddin, M, 2015)	0.81
" The observation of a shorter terminal half-life for lumefantrine may have contributed to a higher frequency of reinfection or a shorter posttreatment prophylactic period in pregnant women than in nonpregnant adults."	( Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria. Achan, J; Aweeka, F; Huang, L; Kajubi, R; Kiconco, S; Mwebaza, N; Mwima, MW; Nguyen, VK; Nyunt, MM; Parikh, S; Ssebuliba, J, 2015)	1.06
" The pharmacokinetic parameters of tafenoquine, piperaquine, lumefantrine, artemether, and dihydroartemisinin were determined by using noncompartmental methods."	( Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects. Bouhired, S; Duparc, S; Goyal, N; Green, JA; Hussaini, A; Jones, SW; Koh, GC; Kostov, I; Mohamed, K; Taylor, M; Wolstenholm, A, 2016)	0.89
"Pregnancy has considerable effects on the pharmacokinetic properties of drugs used to treat uncomplicated Plasmodium falciparum malaria."	( Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. Aklillu, E; Asghar, M; Färnert, A; Homann, MV; Kamuhabwa, AAR; Massawe, SN; Minzi, OMS; Mutagonda, RF, 2017)	0.73
" Pharmacokinetic parameters (area under the plasma concentration vs."	( Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. Aweeka, FT; Barlow-Mosha, L; Carey, V; Gingrich, D; Graham, B; Huang, L; Kamthunzi, P; Lindsey, JC; Marzan, F; Nachman, S; Parikh, S; Ssemambo, PK, 2017)	0.68
" Fifteen of the 16 (aged 4 to 11 years) on nevirapine-based ART were included in the pharmacokinetic analysis."	( Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. Aweeka, FT; Barlow-Mosha, L; Carey, V; Gingrich, D; Graham, B; Huang, L; Kamthunzi, P; Lindsey, JC; Marzan, F; Nachman, S; Parikh, S; Ssemambo, PK, 2017)	0.68
" A population pharmacokinetic meta-analysis was conducted using individual participant data from 10 studies with 6,100 lumefantrine concentrations from 793 nonpregnant adult participants (41% HIV-malaria-coinfected, 36% malaria-infected, 20% HIV-infected, and 3% healthy volunteers)."	( An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. Aweeka, FT; Barnes, KI; Byakika-Kibwika, P; Bygbjerg, IC; Chijioke-Nwauche, I; Denti, P; Francis, J; Hoglund, RM; Khoo, SH; Kredo, T; Lamorde, M; Lemnge, MM; Merry, C; Nyagonde, N; Parikh, S; Scarsi, KK; Sutherland, CJ; Tarning, J; Vestergaard, LS; Walimbwa, SI; Workman, L, 2020)	0.98
" The pharmacokinetic results indicated that the disposition of LFN enantiomers was stereoselective in mice."	( Enantioselective LC-ESI-MS/MS method for quantitation of (-)-lumefantrine and (+)-lumefantrine in mice plasma and application to a pharmacokinetic study. Bajantri, M; Balaji, N; Chandran, R; Dixit, A; Gabani, BB; Kiran, V; Mullangi, R; Srinivas, NR, 2020)	0.8
"The aim of this study was to assess the pharmacokinetic properties of artemether, lumefantrine and their active metabolites in Plasmodium knowlesi malaria."	( The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria. Davis, TME; Davis, WA; Hii, KC; Page-Sharp, M; Salman, S; Singh, B; Sugiarto, SR, 2022)	1.2
" Multi-compartmental population pharmacokinetic models were developed using plasma with or without DBS drug concentrations."	( The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria. Davis, TME; Davis, WA; Hii, KC; Page-Sharp, M; Salman, S; Singh, B; Sugiarto, SR, 2022)	0.98
" DBS lumefantrine concentrations can be used in pharmacokinetic studies but DBS technology is currently unreliable for the other analytes."	( The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria. Davis, TME; Davis, WA; Hii, KC; Page-Sharp, M; Salman, S; Singh, B; Sugiarto, SR, 2022)	1.49

Excerpt	Reference	Relevance
" Of these 16 new anilides administered orally as one 6 mg/kg dose combined with 18 mg/kg mefloquine hydrochloride, only sulfide 3-arteSanilide 12d was completely curative: on day 30 after infection, all mice in this group had no detectable parasitemia, gained as much weight as the uninfected control mice, and behaved normally."	( Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine. Girdwood, SC; Mott, BT; Nenortas, E; Posner, GH; Shapiro, TA; Slack, RD; Sullivan, D; Tripathi, A; Triphati, A; Woodard, LE, 2012)	0.38
" We undertook two pharmacokinetic studies in healthy volunteers, using standard adult doses of artemether-lumefantrine or artesunate-amodiaquine given with 50 mg once daily dolutegravir (DTG) to investigate the drug-drug interaction between artemether-lumefantrine or artesunate-amodiaquine and dolutegravir."	( Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. Amara, A; Byakika-Kibwika, P; Chiong, J; Else, L; Gini, J; Kaboggoza, J; Khoo, SH; Lamorde, M; Tarning, J; Waitt, C; Walimbwa, SI; Winterberg, M, 2019)	0.98
"Treating malaria in HIV-coinfected individuals should consider potential drug-drug interactions."	( An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. Aweeka, FT; Barnes, KI; Byakika-Kibwika, P; Bygbjerg, IC; Chijioke-Nwauche, I; Denti, P; Francis, J; Hoglund, RM; Khoo, SH; Kredo, T; Lamorde, M; Lemnge, MM; Merry, C; Nyagonde, N; Parikh, S; Scarsi, KK; Sutherland, CJ; Tarning, J; Vestergaard, LS; Walimbwa, SI; Workman, L, 2020)	0.77

Excerpt	Reference	Relevance
" The variability in bioavailability of artemether and dihydroartemisinin was large both between doses and between patients, but was less pronounced for benflumetol."	( Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Ezzet, F; Karbwang, J; Mull, R, 1998)	0.3
" Lumefantrine could be estimated accurately enough to assess bioavailability and treatment compliance on day 7 (i."	( Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper. Annerberg, A; Bergqvist, Y; Björkman, A; Blessborn, D; Lindegardh, N; Römsing, S; Sundquist, D, 2007)	1.46
" Therefore, we evaluated the effect of food intake on oral lumefantrine bioavailability in African children with malaria."	( The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria. Björkman, A; Borrmann, S; D'Alessandro, U; Djimdé, A; González, R; Hamel, M; Juma, E; Kern, SE; Lefèvre, G; Machevo, S; Marrast, AC; Mårtensson, A; Ogutu, B; Peshu, J; Sallas, WM, 2010)	0.88
" Similarly, consumption of milk (the most common meal) increased model-estimated lumefantrine bioavailability by 57% (90% CI: 29-96%) with crushed tablets and 65% (90% CI: 28-109%) with dispersible tablets compared to no food."	( The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria. Björkman, A; Borrmann, S; D'Alessandro, U; Djimdé, A; González, R; Hamel, M; Juma, E; Kern, SE; Lefèvre, G; Machevo, S; Marrast, AC; Mårtensson, A; Ogutu, B; Peshu, J; Sallas, WM, 2010)	0.87
" Although artemether bioavailability was variable and its clearance increased by 67."	( Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. Davis, TM; Griffin, S; Ilett, KF; Kose, K; Mueller, I; Page-Sharp, M; Salman, S; Siba, PM, 2011)	0.63
"5 mg/kg dose following administration through the lateral tail vein in order to obtain the absolute oral bioavailability and clearance parameters."	( Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats. Jain, GK; Nafis, A; Puri, SK; Raju, KS; Singh, SP, 2011)	0.58
" The absolute oral bioavailability of lumefantrine was found to be dose dependent."	( Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats. Jain, GK; Nafis, A; Puri, SK; Raju, KS; Singh, SP, 2011)	0.85
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."	( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011)	0.37
"The objective of this study was to compare different methods of adjusted indirect comparisons that can be used to investigate the relative bioavailability of different generic products."	( Statistical approaches to indirectly compare bioequivalence between generics: a comparison of methodologies employing artemether/lumefantrine 20/120 mg tablets as prequalified by WHO. García-Arieta, A; Gordon, J; Gwaza, L; Hansson, H; Potthast, H; Stahl, M; Welink, J, 2012)	0.58
"Data from three bioequivalence studies conducted independently that compared three generics with the same reference product were used to indirectly determine the relative bioavailability between the generics themselves."	( Statistical approaches to indirectly compare bioequivalence between generics: a comparison of methodologies employing artemether/lumefantrine 20/120 mg tablets as prequalified by WHO. García-Arieta, A; Gordon, J; Gwaza, L; Hansson, H; Potthast, H; Stahl, M; Welink, J, 2012)	0.58
"Existence of anti-malarial generic drugs with low bioavailability marketed on sub-Saharan Africa raises a concern on patients achieving therapeutic concentrations after intake of such products."	( Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator's product. Abdulla, S; Chemba, M; Juma, O; Marealle, IA; Minzi, OM; Ngaimisi, E; Rutaihwa, M; Sasi, P; Shekalaghe, S, 2013)	0.6
" The most widely available generic (Artefan®, Ajanta Pharma Ltd, Maharashtra, India) was sampled for bioavailability comparison with Coartem® (Novartis Pharma, Basel, Switzerland)--the innovator's product."	( Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator's product. Abdulla, S; Chemba, M; Juma, O; Marealle, IA; Minzi, OM; Ngaimisi, E; Rutaihwa, M; Sasi, P; Shekalaghe, S, 2013)	0.6
"In the quest to explore the reason for the low and variable bioavailability of lumefantrine, we investigated the possible role of P-glycoprotein (P-gp) in lumefantrine intestinal absorption."	( Investigation of the functional role of P-glycoprotein in limiting the oral bioavailability of lumefantrine. Raju, KS; Singh, SP; Taneja, I, 2014)	0.85
" Upon coadministration of 97-78, the relative bioavailability of lumefantrine significantly decreased to 64."	( Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97-78 in rat plasma using the HPLC-ESI-MS/MS method: application to drug interaction study. Gayen, JR; Raju, KS; Siddiqui, HH; Singh, SK; Singh, SP; Taneja, I; Wahajuddin, M, 2015)	0.88
" Patients in the EFV-arm but not in the NVP-arm had significantly lower lumefantrine bioavailability compared to that in the control-arm."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.87
"Co-treatment of AL with EFV-based ART but not NVP-based ART significantly reduces lumefantrine bioavailability and consequently total exposure."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.86
" In previous studies we reported on the ability of Pheroid vesicles to improve the bioavailability of poorly soluble drugs."	( In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology. Denti, P; du Plessis, LH; Govender, K; Wiesner, L, 2015)	0.68
"Oral delivery and bioavailability of artemether and lumefantrine could be improved using SRMS-based SLMs."	( Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles. Agbo, C; Agubata, O; Attama, A; Chime, S; Kenechukwu, F; Lovelyn, C; Ofokansi, K; Ogbonna, J; Umeyor, C, 2016)	0.9
" Age had a significant positive correlation with bioavailability in a model that included allometric scaling."	( Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria. Arinaitwe, E; Aweeka, FT; Bergqvist, Y; Bigira, V; Blessborn, D; Creek, DJ; Kakuru, A; McCormack, SA; Muhindo, M; Parikh, S; Sambol, NC; Sukumar, N; Tappero, JW; Tchaparian, E; Wanzira, H, 2016)	0.68
" In an attempt to enhance the bioavailability of lumefantrine, new solid dispersion formulations (SDF) were developed, and the pharmacokinetics of two SDF variants were assessed in a randomized, open-label, sequential two-part study in healthy volunteers."	( Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers. Chen, L; Jain, JP; Kalluri, S; Koradia, V; Kota, J; Leong, FJ; Stein, DS; Sunkara, G; Wolf, MC, 2017)	1.04
" Lumefantrine, an anti-malaria drug, was chosen as a representative drug that was processed into 200 nm nanoparticles with enhanced bioavailability and dissolution kinetics."	( Translational formulation of nanoparticle therapeutics from laboratory discovery to clinical scale. Armstrong, M; Feng, J; Markwalter, CE; Prud'homme, RK; Tian, C, 2019)	1.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Herein, the amorphous solid dispersions (SD) of lumefantrine (LUMF) containing piperine (PIP), a P-gp and CYP3A4 inhibitor, were formulated with Soluplus (Sol), Klucel (Klu) and Lutrol F68 (Lut), polymeric carriers, to improve solubility and bioavailability of LUMF following oral administration."	( Lumefantrine solid dispersions with piperine for the enhancement of solubility, bioavailability and anti-parasite activity. Aji, A; Deshmukh, PR; Ghule, BV; Inamdar, NN; Jane, K; Khade, RR; Kotagale, NR; Pendharkar, VV; Takale, NR, 2022)	2.42
" However, LMN's therapeutic efficacy is diminished due to its low bioavailability when dosed as a crystalline solid."	( Formulation and Scale-Up of Fast-Dissolving Lumefantrine Nanoparticles for Oral Malaria Therapy. Armstrong, M; Ma, L; Nagapudi, K; Panmai, S; Prud'homme, RK; Ristroph, K; Tian, C; Wang, L; Yang, J; Zhang, D, 2023)	1.17

Excerpt	Relevance	Reference
" Characterisation of these pharmacokinetic-pharmacodynamic relationships provided the basis for dosage optimisation, an approach that could be applied to other antimalarial drugs."	( Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Ezzet, F; van Vugt, M; White, NJ, 1999)	0.53
" The high adherence to artemether-lumefantrine found in our study suggest that this drug is likely to be very effective in Mbarara provided that patients receive clear dosage explanations."	( Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Bajunirwe, F; Biraro, S; Checchi, F; Fogg, C; Guthmann, JP; Kiguli, J; Kyomugisha, A; Musabe, J; Namiiro, P; Piola, P, 2004)	0.86
" Insufficient numbers of tablets and inadequate package inserts result in sub-optimal dosing and possible treatment failure."	( Malaria treatment failures after artemisinin-based therapy in three expatriates: could improved manufacturer information help to decrease the risk of treatment failure? Chappuis, F; Jackson, Y; Loutan, L; Taylor, W, 2006)	0.33
" The aim of this study was to describe the dose-response relationship between coadministration of fat and relative lumefantrine bioavailability, in order to determine the minimum amount of fat necessary to optimize absorption."	( How much fat is necessary to optimize lumefantrine oral bioavailability? Annerberg, A; Ashley, EA; Brockman, A; Kham, A; Lindegårdh, N; Nosten, F; Singhasivanon, P; Stepniewska, K; White, NJ, 2007)	0.82
"A dose-response relationship was demonstrated between the volume of soya milk administered and lumefantrine bioavailability."	( How much fat is necessary to optimize lumefantrine oral bioavailability? Annerberg, A; Ashley, EA; Brockman, A; Kham, A; Lindegårdh, N; Nosten, F; Singhasivanon, P; Stepniewska, K; White, NJ, 2007)	0.83
" Mothers/guardians of children were asked about fever in the last 14 days and related treatment actions including the timing, drugs used, dosing and adherence supported by visual aids of commonly available drug products."	( The use of artemether-lumefantrine by febrile children following national implementation of a revised drug policy in Kenya. Ajanga, A; Amin, AA; Gitonga, CW; Kangwana, BB; Noor, AM; Snow, RW, 2008)	0.66
" However, AL has several limitations, including a twice-daily dosing regimen, recommendation for administration with fatty food, and a high risk of reinfection soon after therapy in high transmission areas."	( Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. Bukirwa, H; Dorsey, G; Kamya, MR; Lugemwa, M; Rosenthal, PJ; Rwakimari, JB; Staedke, SG; Talisuna, A; Wabwire-Mangen, F; Yeka, A, 2008)	0.74
"DP is highly efficacious, and operationally preferable to AL because of a less intensive dosing schedule and requirements."	( Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. Bukirwa, H; Dorsey, G; Kamya, MR; Lugemwa, M; Rosenthal, PJ; Rwakimari, JB; Staedke, SG; Talisuna, A; Wabwire-Mangen, F; Yeka, A, 2008)	0.74
" The greatest effort in the home management of malaria strategy should be in reducing delay in treatment and improving dosage and duration of treatment."	( Community effectiveness of artemisinin-based combination therapy for malaria in rural southwestern Nigeria. Ajayi, IO; Falade, CO; Gbotosho, GO; Happi, TC; Pagnoni, F; Yusuf, OB, )	0.13
" Pharmacokinetic (PK) data informing the optimum dosing of these drug regimens is limited, especially in children."	( Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Annerberg, A; Aweeka, F; Clark, TD; Dorsey, G; Drysdale, T; German, P; Kalyango, JN; Kamya, MR; Lindegardh, N; McGee, B; Mwesigwa, J; Parikh, S; Rosenthal, PJ, 2010)	0.65
" falciparum malaria in central Sudan, although treatment with DHA-P (which requires a simpler dosing regimen) might be preferred to treatment with AL."	( Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan. Adam, I; Elhassan, AH; Elmardi, KA; Eltahir, HG; Malik, EM; Salah, MT, 2010)	0.62
" Patients were randomized to 3 different dosing groups (weights of 5 to <15 kg, 15 and <25 kg, and 25 to <35 kg)."	( Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. Abdulla, S; Bassat, Q; Borrmann, S; Djimdé, AA; Lefèvre, G; Lyimo, J; Mandomando, I; Tekete, M, 2011)	0.59
" Simultaneously, the feared development of parasite drug resistance might drive dosing increases."	( The pharmacogenetics of antimalaria artemisinin combination therapy. Gil, JP; Piedade, R, 2011)	0.37
" In the three AL body weight dosing groups (5 to < 15 kg, 15 to < 25 kg and 25 to < 35 kg), 80% of patients were aged 10-50 months, 46-100 months and 90-147 months, respectively."	( Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges. Bashraheil, M; Bassat, Q; González, R; Kipkeu, C; Lefèvre, G; Lyimo, J; Machevo, S; Maiga, H; Mårtensson, A; Menéndez, C; Nahum, A; Nwaiwu, O; Ogutu, B; Ouma, P; Ubben, D; Walter, V, 2011)	0.63
"Efficacy of AL in uncomplicated falciparum malaria is similar across body weight dosing groups as currently recommended in the label with no clinically relevant differences in safety or tolerability."	( Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges. Bashraheil, M; Bassat, Q; González, R; Kipkeu, C; Lefèvre, G; Lyimo, J; Machevo, S; Maiga, H; Mårtensson, A; Menéndez, C; Nahum, A; Nwaiwu, O; Ogutu, B; Ouma, P; Ubben, D; Walter, V, 2011)	0.63
" Many controversies were identified, including pharmacokinetic equivalence of novel dosage forms, altered pharmacokinetic parameters in children versus adults, effect of drug interactions, and association of pharmacokinetic changes with clinical outcomes."	( Pharmacokinetic profile of artemisinin derivatives and companion drugs used in artemisinin-based combination therapies for the treatment of Plasmodium falciparum malaria in children. Ensom, MH; Pawluk, SA; Wilby, KJ, 2013)	0.39
"In the first study, the toxicity of artemether was evaluated in juvenile rats dosed with 0, 10, 30, and 100mg/kg/day on postpartum days (ppds) 7 to 21."	( Neurotoxicity assessment of artemether in juvenile rats. Beckman, DA; Butt, MT; Youreneff, M, 2013)	0.39
" More studies with appropriate control groups in larger series are needed to characterize the degree to which pregnant women are underdosed with current antimalarial dosing regimens."	( Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda. Dhorda, M; Guerin, PJ; Jullien, V; Kloprogge, F; Nosten, F; Piola, P; Tarning, J; White, NJ, 2013)	0.63
" Optimal lumefantrine dosage regimen for patients on EFV-based ART was determined by population pharmacokinetics and simulation."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	1.05
" The predictive model through simulation of lumefantrine exposure at different dosage regimen scenarios for patients on EFV-based ART, suggest that AL taken twice daily for five days using the current dose could improve lumefantrine exposure and consequently malaria treatment outcomes."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.89
"Specially created pediatric formulations have the potential to improve the acceptability, effectiveness, and accuracy of dosing of artemisinin-based combination therapy (ACT) in young children, a patient group that is inherently vulnerable to malaria."	( Tailoring a Pediatric Formulation of Artemether-Lumefantrine for Treatment of Plasmodium falciparum Malaria. Bassat, Q; Djimde, A; Hamed, K; Ogutu, B; Stricker, K, 2015)	0.67
"Current artemether-lumefantrine dosing recommendations achieve day 7 lumefantrine concentrations ≥200 ng/ml and high cure rates in most uncomplicated malaria patients."	( Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. , 2015)	1.14
" The safety profiles of artesunate-mefloquine and artemether-lumefantrine were similar, with low rates of early vomiting (71 [15·3%] of 463 patients in the artesunate-mefloquine group vs 79 [16·8%] of 471 patients in the artemether-lumefantrine group in any of the three dosing days), few neurological adverse events (ten [2·1%] of 468 vs five [1·1%] of 465), and no detectable psychiatric adverse events."	( Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. Ackermann, I; Aubin, F; Carn, G; Gesase, S; Lusingu, JPA; Mnkande, E; Mrango, Z; Mtoro, A; Ngocho, JS; Ogutu, B; Onyango, KO; Ouedraogo, A; Sirima, SB; Strub, N; Vanraes, J; Yaro, JB, 2016)	0.93
" Further refinement of artemether-lumefantrine dosing to improve exposure in infants and very young children may be warranted."	( Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria. Arinaitwe, E; Aweeka, FT; Bergqvist, Y; Bigira, V; Blessborn, D; Creek, DJ; Kakuru, A; McCormack, SA; Muhindo, M; Parikh, S; Sambol, NC; Sukumar, N; Tappero, JW; Tchaparian, E; Wanzira, H, 2016)	0.96
" However, the reduction in artemisinin exposure may warrant further study, and suggests that dosage adjustment of artemether-lumefantrine with nevirapine-based ART in children is likely warranted."	( Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. Aweeka, FT; Barlow-Mosha, L; Carey, V; Gingrich, D; Graham, B; Huang, L; Kamthunzi, P; Lindsey, JC; Marzan, F; Nachman, S; Parikh, S; Ssemambo, PK, 2017)	0.88
" The available data suggest that ganaplacide exerts multi-stage antimalarial activity, and that its pharmacokinetic profile potentially allows for a simplified dosing regimen compared to that of existing antimalarial drug combinations."	( The early preclinical and clinical development of ganaplacide (KAF156), a novel antimalarial compound. Grobusch, MP; Koller, R; Mombo-Ngoma, G, 2018)	0.48
" Coupling nanoparticle production using FNP processing with spray drying offers a continuous nanofabrication platform to scale up nanoparticle synthesis and processing into solid dosage forms."	( Translational formulation of nanoparticle therapeutics from laboratory discovery to clinical scale. Armstrong, M; Feng, J; Markwalter, CE; Prud'homme, RK; Tian, C, 2019)	0.51
" These data suggest that malaria and HIV coinfected pregnant women may require adjustments in AL dosage or treatment duration to achieve exposure comparable with HIV-uninfected pregnant women."	( Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women. Aweeka, F; Huang, L; Hughes, E; Kajubi, R; Mwebaza, N; Mwima, MW; Nguyen, V; Nyunt, MM; Orukan, F; Parikh, S, 2020)	0.8
"Good powder flow is critical for powders destined for inclusion into tablets - especially when employing direct compression as method of manufacture - in this case, lipid matrix tablets, which have demonstrated huge promise as a prospective dosage form for future use in malarial treatment."	( Characterization of solid lipid dispersions prepared by hot fusion containing a double-fixed dose combination of artemether and lumefantrine. du Plessis, LH; Viljoen, JM; Wilkins, CA, 2020)	0.76
" Dosing is suboptimal in young children."	( The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial. Aweeka, FT; Colt, M; Goodwin, J; Huang, L; Kajubi, R; Li, F; Mwebaza, N; Orukan, F; Parikh, S; Richards, K; Wang, K; Whalen, ME, 2023)	1.16
" Participants were randomly allocated 1:1 to antimalarial chemoprophylaxis, a 3-day course of twice-daily artemether-lumefantrine followed by the same daily dosing once a week while travelling in the forest and for a further 4 weeks after leaving the forest (four tablets per dose; 20 mg of artemether and 120 mg of lumefantrine per tablet), or a multivitamin with no antimalarial activity."	( Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial. Callery, JJ; Chotthanawathit, P; Conradis-Jansen, F; Dondorp, AM; Duanguppama, J; Ean, M; Heng, C; Imwong, M; Jongdeepaisal, M; Khonputsa, P; Madmanee, W; Maude, RJ; Mukaka, M; Peerawaranun, P; Pell, C; Peto, TJ; Pongsoipetch, K; Rekol, H; Sokha, M; Sovannaroth, S; Soviet, U; Tarning, J; Tripura, R; von Seidlein, L; Waithira, N; White, NJ, 2023)	1.12
" However, LMN's therapeutic efficacy is diminished due to its low bioavailability when dosed as a crystalline solid."	( Formulation and Scale-Up of Fast-Dissolving Lumefantrine Nanoparticles for Oral Malaria Therapy. Armstrong, M; Ma, L; Nagapudi, K; Panmai, S; Prud'homme, RK; Ristroph, K; Tian, C; Wang, L; Yang, J; Zhang, D, 2023)	1.17

Role	Description
antimalarial	A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
tertiary amine	A compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups.
monochlorobenzenes	Any member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
secondary alcohol	A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
fluorenes	An ortho-fused polycyclic arene in which the skeleton is composed of two benzene rings ortho-fused to cyclopentane.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
acetylcholinesterase	Homo sapiens (human)	Potency	34.6713	0.0025	41.7960	15,848.9004	AID1347398
phosphopantetheinyl transferase	Bacillus subtilis	Potency	84.3927	0.1413	37.9142	100.0000	AID1490; AID2701; AID2707
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	29.8493	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
SMAD family member 2	Homo sapiens (human)	Potency	23.9145	0.1737	34.3047	61.8120	AID1346859
SMAD family member 3	Homo sapiens (human)	Potency	23.9145	0.1737	34.3047	61.8120	AID1346859
GLI family zinc finger 3	Homo sapiens (human)	Potency	13.4888	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	8.4852	0.0002	21.2231	8,912.5098	AID743035
caspase 7, apoptosis-related cysteine protease	Homo sapiens (human)	Potency	33.4915	0.0133	26.9810	70.7614	AID1346978
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	25.2840	0.0010	22.6508	76.6163	AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	26.8243	0.0123	7.9835	43.2770	AID1346984; AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	26.8325	0.0002	14.3764	60.0339	AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	13.7143	0.0030	41.6115	22,387.1992	AID1159552; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	26.8325	0.0008	17.5051	59.3239	AID1159527
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	33.8191	0.0015	30.6073	15,848.9004	AID1224848; AID1224849; AID1259403
pregnane X nuclear receptor	Homo sapiens (human)	Potency	10.3297	0.0054	28.0263	1,258.9301	AID1346982; AID1346985
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	23.7101	0.0002	29.3054	16,493.5996	AID743079
G	Vesicular stomatitis virus	Potency	21.8761	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	0.3467	0.0010	8.3798	61.1304	AID1645840
caspase-3	Homo sapiens (human)	Potency	33.4915	0.0133	26.9810	70.7614	AID1346978
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	25.1567	0.0007	23.0674	1,258.9301	AID743085; AID743122
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	2.6832	19.7391	45.9784	64.9432	AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	22.6142	0.0578	21.1097	61.2679	AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus (Norway rat)	Potency	25.1189	0.1000	9.1916	31.6228	AID1346983
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	61.9315	0.0391	47.5451	146.8240	AID1224845; AID1224896
Caspase-7	Cricetulus griseus (Chinese hamster)	Potency	33.4915	0.0067	23.4960	68.5896	AID1346980
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	12.5893	0.0178	9.6374	44.6684	AID588834
caspase-3	Cricetulus griseus (Chinese hamster)	Potency	33.4915	0.0067	23.4960	68.5896	AID1346980
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	29.8493	0.0003	23.4451	159.6830	AID743065; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	33.4889	0.0420	27.3789	61.6448	AID743210
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	19.9526	0.0079	8.2332	1,122.0200	AID2546
geminin	Homo sapiens (human)	Potency	23.7150	0.0046	11.3741	33.4983	AID624297
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	32.1968	0.0056	12.3677	36.1254	AID624032
Interferon beta	Homo sapiens (human)	Potency	21.8761	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	21.8761	0.0123	8.9648	39.8107	AID1645842
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	21.8761	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	21.8761	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	5.5351	0.0009	1.9014	10.0000	AID1445968; AID240820; AID576612
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (149)

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID558832	Antimalarial activity against Plasmodium falciparum HB3 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID497995	AUC (0-infinity) in Ugandan children patient with uncomplicated malaria administered twice daily for 3 days as 20/120 mg tablets containing artemether-lumefantrine combination	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
AID582696	Cmax in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 5 days coadministered with 20 mg artemether by two-compartment population pharmacokinetic model	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID562112	Selectivity ratio of IC50 for Plasmodium falciparum 3D7 to IC50 for multidrug-resistant Plasmodium falciparum VS/1	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID558836	Antimalarial activity against Plasmodium falciparum IMT A4 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID564240	Antiplasmodial activity against Plasmodium falciparum harboring mutant pfcrt-76 and wild type pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID564242	Antiplasmodial activity against Plasmodium falciparum harboring wild type pfcrt-76 and wild type pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID558837	Antimalarial activity against Plasmodium falciparum IMT 31 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1168868	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human type A-positive red blood cells assessed as growth inhibition after 72 hrs by spectrophotometrically	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Synthesis and evaluation of the antiplasmodial activity of novel indeno[2,1-c]quinoline derivatives.
AID582702	Drug concentration in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether measured after 7 days by two-compartment populati	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID1168869	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human type A-positive red blood cells assessed as growth inhibition after 72 hrs by spectrophotometrically	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Synthesis and evaluation of the antiplasmodial activity of novel indeno[2,1-c]quinoline derivatives.
AID558841	Antimalarial activity against Plasmodium falciparum IMT 10500 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID582709	Apparent volume of distribution in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population pharma	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID582700	Drug concentration in pregnant human with uncomplicated multidrug-resistant Plasmodium falciparum malaria infection at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID240820	Inhibitory concentration against IKr potassium channel	2004	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18	The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
AID564239	Antiplasmodial activity against Plasmodium falciparum harboring mutant pfcrt-76 and mutant pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID1593291	Antimalarial activity against drug-resistant Plasmodium falciparum 3D7 harboring A82T/V259L double mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID582704	Terminal elimination half-life in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population pharmac	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID497987	Half life in Ugandan children patient with uncomplicated malaria administered twice daily for 3 days as 20/120 mg tablets containing artemether-lumefantrine combination	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
AID564232	Antiplasmodial activity against Plasmodium falciparum clinical isolate after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID519195	Antimicrobial activity against Plasmodium vivax trophozoites measured after 30 hrs by microscopy	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID558844	Antimalarial activity against Plasmodium falciparum IMT K2 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID582694	Cmax in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 5 days coadministered with 20 mg artemether measured after 7 days by two-compartment population pharmacokin	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID558840	Antimalarial activity against Plasmodium falciparum IMT 10336 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID562110	Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID558834	Antimalarial activity against Plasmodium falciparum IMT Bres assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID582697	Cmax in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 4 days coadministered with 20 mg artemether by two-compartment population pharmacokinetic model	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID643459	Antimalarial activity against Plasmodium berghei ANKA infected in C57BL/6 mouse assessed as decrease in parasitemia at 18 mg/kg, po administered 24 hrs post-infection measured after 3 days by Giemsa microscopy relative to vehicle treated control	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.
AID519197	Antimicrobial activity against Plasmodium vivax trophozoites measured within 30 hrs by microscopy	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID529905	Antiplasmodial activity against Plasmodium falciparum harboring K1 allele group of msp1, 3D7 allele group of msp2 gene and 94 bp of 7A11, 196bp of C4M79 and 336bp of C4M69 locus measured on day 23 by [3H]hypoxanthine incorporation assay	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.
AID558829	Antimalarial activity against Plasmodium falciparum FCM29 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1593290	Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID519196	Antimicrobial activity against Plasmodium vivax at the ring stage measured after 30 hrs by microscopy	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID449703	NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay	2008	Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26	In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID547315	Antimalarial activity against Plasmodium falciparum	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
AID582706	Absorption rate constant in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population pharmacokinet	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID1593253	Antimalarial activity against multidrug-resistant Plasmodium falciparum Dd2 infected in human erythrocytes by SYBR green 1-based fluorescence assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID511252	Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum W2 by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID582705	Volume of distribution at steady state in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID558830	Antimalarial activity against Plasmodium falciparum FCR3 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID511251	Antimicrobial activity against Plasmodium falciparum by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID582698	Cmax in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population pharmacokinetic model	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID564235	Antiplasmodial activity against Plasmodium falciparum harboring mutant pfcrt-76 gene after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID564238	Antiplasmodial activity against Plasmodium falciparum harboring wild type and mutant pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID158865	Antimalarial activity against Plasmodium falciparum Dd2 in erythrocytes	2002	Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4	Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.
AID558838	Antimalarial activity against Plasmodium falciparum IMT 8425 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID449705	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	2008	Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26	In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID643456	Antimalarial activity against Plasmodium berghei ANKA infected in C57BL/6 mouse assessed as host survival at 18 mg/kg, po administered 24 hrs post-infection (Rvb = 6.8 days)	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine.
AID1688324	Antimalarial activity against Plasmodium falciparum 3D7A asexual forms assessed as inhibition of [G-3H]hypoxanthine uptake incubated for 24 hrs followed by [G-3H]hypoxanthine addition and measured after 18 hrs by liquid scintillation spectrometry	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
AID511255	Antimicrobial activity against chloroquine-resistant Plasmodium falciparum K1 by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID576612	Inhibition of human ERG	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID582710	Clearance in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population pharmacokinetic model	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID582701	Drug concentration in pregnant human patient with reappeared uncomplicated multidrug-resistant Plasmodium falciparum malaria infection at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID635308	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2mef infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs by beta liquid scintillation counting method	2011	Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24	Synthesis and antimalarial evaluation of novel isocryptolepine derivatives.
AID558835	Antimalarial activity against Plasmodium falciparum IMT Guy assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID558827	Antimalarial activity against Plasmodium falciparum W2 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID558847	Antimalarial activity against Plasmodium falciparum IMT Vol assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID582708	Intercompartmental clearance in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population pharmacok	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID582703	AUC (0 to infinity) in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment population pharmacokinetic mo	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID1593288	Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring M133I/A138T double mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID564230	Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID1168867	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in human type A-positive red blood cells assessed as growth inhibition after 72 hrs by spectrophotometrically	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Synthesis and evaluation of the antiplasmodial activity of novel indeno[2,1-c]quinoline derivatives.
AID748941	Terminal half life in human	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Recent advances in malaria drug discovery.
AID582695	Cmax in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 4 days coadministered with 20 mg artemether measured after 7 days by two-compartment population pharmacokin	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID564234	Antiplasmodial activity against Plasmodium falciparum harboring wild type and mutant pfcrt-76 gene after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID564237	Antiplasmodial activity against Plasmodium falciparum harboring mutant pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID558843	Antimalarial activity against Plasmodium falciparum IMT K14 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID564241	Antiplasmodial activity against Plasmodium falciparum harboring wild type pfcrt-76 and mutant pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID158864	Antimalarial activity against Plasmodium falciparum 3D7 in erythrocytes	2002	Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4	Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.
AID497988	Cmax in Ugandan children patient with uncomplicated malaria administered twice daily for 3 days as 20/120 mg tablets containing artemether-lumefantrine combination	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
AID449706	NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.	2008	Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26	In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1445968	Inhibition of human ERG by fluorescence polarization assay	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID519198	Antimicrobial activity against Plasmodium vivax at the ring stage measured within 30 hrs by microscopy	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID558845	Antimalarial activity against Plasmodium falciparum IMT K4 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID564236	Antiplasmodial activity against Plasmodium falciparum harboring wild type pfmdr-1-86 gene after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID1649432	Antimalarial activity against Plasmodium falciparum clinical isolates measured after 72 hrs by SYBR green dye based fluorescence assay	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
AID449704	NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay	2008	Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26	In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID582711	Cmax in venous plasma of pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 5 days coadministered with 20 mg artemether measured on 7 days by two-compartment populati	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID511254	Antimicrobial activity against chloroquine-resistant Plasmodium falciparum HB3 by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID511253	Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum D6 by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID558833	Antimalarial activity against Plasmodium falciparum 106/1 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID558828	Antimalarial activity against Plasmodium falciparum D6 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID558831	Antimalarial activity against Plasmodium falciparum PA assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID564231	Antiplasmodial activity against multidrug-sensitive Plasmodium falciparum 3D7 after 18 hrs by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
AID1593289	Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring M133I mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID562111	Antiplasmodial activity against Plasmodium falciparum 3D7 by [3H]hypoxanthine incorporation assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID558842	Antimalarial activity against Plasmodium falciparum IMT 16332 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID157697	Anti-malarial activity against Plasmodium falciparum Dd2	2003	Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3	Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
AID157697	Anti-malarial activity against Plasmodium falciparum Dd2	2003	Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9	Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
AID1593287	Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring V259L mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID497976	AUC (0-120 hrs) in Ugandan children patient with uncomplicated malaria assessed as dihydroartemisin administered twice daily for 3 days as 20/120 mg tablets containing artemether-lumefantrine combination	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
AID158715	Inhibition against Plasmodium falciparum Dd2 in erythrocytes in semiautomated micro dilution assay	2003	Bioorganic & medicinal chemistry letters, Jul-07, Volume: 13, Issue:13	Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties.
AID558826	Antimalarial activity against Plasmodium falciparum 3D7 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID582707	Apparent peripheral volume of distribution in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether by two-compartment popula	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID748936	Antiplasmodial activity against multidrug-resistant Plasmodium falciparum W2 infected in human erythrocytes	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Recent advances in malaria drug discovery.
AID1593296	Inhibition of Plasmodium falciparum cytochrome b-c1	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID158852	Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes by semiautomated micro dilution	2003	Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3	Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
AID158852	Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes by semiautomated micro dilution	2003	Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9	Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
AID511256	Antimicrobial activity against Plasmodium falciparum harboring mdr1 N86Y/D1246Y/Y184F mutant gene by ELISA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID582712	Tlag in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether measured after 7 days by two-compartment population pharmacokin	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID582693	Cmax in capillary plasma of pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 5 days coadministered with 20 mg artemether measured on 7 days by two-compartment popul	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID558839	Antimalarial activity against Plasmodium falciparum IMT 9881 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID558846	Antimalarial activity against Plasmodium falciparum IMT L1 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID582699	Drug concentration in pregnant human patient with uncomplicated multidrug-resistant Plasmodium falciparum malaria at 120 mg, po administered as 4 tablets BID for 3 days coadministered with 20 mg artemether	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
AID555962	Antimalarial activity against chloroquine-resistant Plasmodium vivax by Giemsa staining	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID602156	Novartis GNF Liver Stage Dataset: Malariabox Annotation	2011	Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061	Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	20 (4.25)	18.2507
2000's	134 (28.45)	29.6817
2010's	243 (51.59)	24.3611
2020's	74 (15.71)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	123 (25.26%)	5.53%
Reviews	34 (6.98%)	6.00%
Case Studies	25 (5.13%)	4.05%
Observational	4 (0.82%)	0.25%
Other	301 (61.81%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (169)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 2 Interventional, Multicenter, Randomized Open Label Study to Determine the Effective and Tolerable Dose of KAF156 and Lumefantrine Solid Dispersion Formulation in Combination, Given Once Daily for 1, 2 and 3-days to Adults and Children With Uncom [NCT03167242]	Phase 2	524 participants (Actual)	Interventional	2017-08-02	Completed
A Multicentre Randomised Comparative Clinical Trial of the Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine (Coartem®) for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Zanzibar [NCT03768908]	Phase 4	359 participants (Actual)	Interventional	2005-01-05	Completed
Surveillance for the Effectiveness and Safety of Artemether-lumefantrine in Pediatric and Adult Patients With Malaria [NCT01228344]		324 participants (Actual)	Observational	2010-05-01	Completed
A Phase 2, Multi-center, Randomized, Open-label, Dose-escalation Study to Determine Safety of Single (QD) and Multiple (3 QD) Doses of KAE609, Given to Adults With Uncomplicated Plasmodium Falciparum Malaria. [NCT03334747]	Phase 2	188 participants (Actual)	Interventional	2017-11-16	Completed
Artemether-lumefantrine vs Chloroquine in Patients With Acute Non-severe P. Vivax Malaria in Sabah, Malaysia [NCT02348788]	Phase 3	98 participants (Anticipated)	Interventional	2015-01-31	Recruiting
A Phase I, Open-label, Fixed-sequence, Two-period, Crossover, Drug-drug Interaction Study to Investigate the Effect of Efavirenz on the Pharmacokinetics of Ganaplacide and Lumefantrine Combination in Healthy Participants [NCT05330273]	Phase 1	14 participants (Actual)	Interventional	2022-04-28	Completed
Efficacy and Safety of a Single Low-dose Primaquine Added to Standard Artemether-lumefantrine Treatment for the Clearance of Plasmodium Falciparum Gametocytes. [NCT02090036]	Phase 4	220 participants (Actual)	Interventional	2014-07-31	Completed
A Four-arm Trial Comparing Artemether-lumefantrine With or Without Single-dose Primaquine and Sulphadoxine-pyrimethamine/Amodiaquine With or Without Single-dose Tafenoquine to Reduce P. Falciparum Transmission in Mali [NCT05081089]	Phase 2	80 participants (Actual)	Interventional	2021-10-12	Completed
Host and Parasites Factors Contributing to Risk of Plasmodium Re-infection and Morbidity in Elementary School Children in Maprik, East Sepik Province [NCT02143934]	Phase 4	524 participants (Actual)	Interventional	2009-08-31	Completed
A Randomized Clinical Trial to Measure the Impact of Retreatment With an Artemisinin-based Combination on Malaria Incidence and Its Potential Selection of Resistant Strains [NCT01374581]	Phase 3	2,117 participants (Actual)	Interventional	2012-05-31	Completed
Efficacy and Safety of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines in 2017-2018 [NCT05958810]		80 participants (Actual)	Observational	2017-01-02	Completed
Optimizing the Dose of Tafenoquine for the Radical Cure of Plasmodium Vivax Malaria in Southeast Asia [NCT04704999]	Phase 4	700 participants (Anticipated)	Interventional	2023-09-18	Not yet recruiting
A Phase I, Open-label, Fixed Sequence, Two-period, Crossover, Drug-drug Interaction Study to Investigate the Interaction Potential of Itraconazole on the Pharmacokinetics of Ganaplacide and Lumefantrine Combination in Healthy Participants [NCT05084651]	Phase 1	19 participants (Actual)	Interventional	2021-11-18	Completed
Evaluation of the Safety of Primaquine in Combination With Artemether-lumefantrine in Glucose-6-phosphate Dehydrogynase Deficient Males With an Asymptomatic Malaria Infection in Burkina Faso (SAFEPRIM) [NCT02174900]	Phase 2/Phase 3	70 participants (Actual)	Interventional	2014-10-31	Completed
Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes [NCT02325180]	Phase 4	338 participants (Actual)	Interventional	2015-01-31	Completed
An Open-label Randomised Trial to Assess the Therapeutic Efficacy and Tolerability of Arterolane-piperaquine Plus Single Low Dose Primaquine Versus Arterolane-piperaquine Plus Mefloquine and Single Low Dose Primaquine Versus Artemether-lumefantrine Plus S [NCT03452475]	Phase 3	219 participants (Actual)	Interventional	2018-03-07	Completed
A Randomised, Open-label Non-inferiority Trial of Artemether-lumefantrine Versus Quinine for the Treatment of Uncomplicated Falciparum Malaria During Pregnancy, Mbarara, Uganda (2006-2007) [NCT00495508]	Phase 4	300 participants (Actual)	Interventional	2006-10-31	Completed
Efficacy of Antimalarial Drugs Used for the Treatment of Uncomplicated Malaria, Plasmodium Falciparum, at the Agadez, Gaya and Tessaoua Sentinel Sites [NCT05070520]	Phase 4	259 participants (Actual)	Interventional	2020-09-01	Completed
Evaluation of the Efficacy of Artemether-lumefantrine and Dihydroartemisinin-piperaquine in Children With Uncomplicated Clinical Malaria in Rural Rwanda [NCT04767217]	Phase 4	528 participants (Anticipated)	Interventional	2021-06-14	Recruiting
Efficacy and Safety of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria and Chloroquine for Plasmodium Vivax in the Philippines From 2013-2014 [NCT04222088]		159 participants (Actual)	Observational	2013-05-01	Completed
Safety and Feasibility of a Malaria Transmission Model in Semi-immune Kenyan Adults Using Plasmodium Falciparum Sporozoites [NCT04280692]	Phase 1/Phase 2	44 participants (Actual)	Interventional	2022-08-22	Active, not recruiting
Monitoring the Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine During the Treatment of Uncomplicated Plasmodium Falciparum Malaria Among Children in Yaounde, Cameroon [NCT04565184]	Phase 4	242 participants (Actual)	Interventional	2019-05-09	Completed
Phase I, Randomized, Parallel Group Study to Evaluate the Effect of Multiple Oral Doses of Eurartesim on the QT/QTc Interval Compared to Riamet, Placebo and Moxifloxacin in Healthy Male and Female Volunteers [NCT01103830]	Phase 1	287 participants (Actual)	Interventional	2010-02-28	Completed
Impact Tanzania in Vivo Efficacy 2010: Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children Aged 6-59 Months [NCT01082705]	Phase 3	323 participants (Actual)	Interventional	2010-04-30	Completed
A Multi-center, Open-label, Randomized Trial of Chloroquine, Artemether-Lumefantrine, and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Vivax Malaria in Pregnant Women in Brazil [NCT01107145]	Phase 4	16 participants (Actual)	Interventional	2011-02-28	Terminated(stopped due to Extremely slow enrollment)
An Adaptive, Randomized, Active-controlled, Open-label, Sequential Cohort, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Intravenous Cipargamin (KAE609) in Adult and Pediatric Participants With Severe Plasmodium [NCT04675931]	Phase 2	252 participants (Anticipated)	Interventional	2022-03-07	Recruiting
Antioxidant Micronutrients in Malaria:a Randomised Clinical Trial [NCT01152931]	Phase 3	10 participants (Actual)	Interventional	2010-08-31	Completed
Randomized Study of the Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate Plus Amodiaquine Coadministered for the Treatment of Uncomplicated Falciparum Malaria in Zanzibar [NCT03764527]	Phase 4	408 participants (Actual)	Interventional	2002-11-01	Completed
Assessing the Effectiveness of Targeted Active Case Detection Among High Risk Populations in Southern Lao PDR [NCT03783299]	Phase 4	39,968 participants (Actual)	Interventional	2017-11-28	Completed
A Cluster Randomized, Single-centre, Controlled, Parallel,12-month Prospective Study and Additional 12-month Follow-up in Africa of Malaria Incidence in a Community Setting Following Systematic Treatment of P. Falciparum Asymptomatic Carriers With Artemet [NCT01256658]	Phase 4	14,075 participants (Actual)	Interventional	2010-11-30	Completed
Open Label, Multicenter Study for Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets (6-Dose Regimen) in African Infants and Children in the Treatment of Acute Uncomplicated Falciparum Malaria [NCT00709969]	Phase 3	310 participants (Actual)	Interventional	2002-07-31	Completed
Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTs [NCT00720811]		6,456 participants (Actual)	Interventional	2009-10-31	Completed
Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa [NCT00677833]	Phase 2/Phase 3	361 participants (Actual)	Interventional	2008-06-30	Completed
Evaluation of the Effect of Artemisinin-based Combination Therapies on Urinary Schistosoma Haematobium When Administered for the Treatment of Malaria Co-infection [NCT04264130]	Phase 2	54 participants (Actual)	Interventional	2018-07-31	Completed
In Vivo and in Vitro Efficacy of the Recommended First Line Antimalarial Treatments (Artemether-Lumefantrine and Amodiaquine-Artesunate) in Children With Uncomplicated Malaria in Burkina Faso [NCT00808951]	Phase 4	440 participants (Actual)	Interventional	2008-12-31	Completed
Safety and Protective Efficacy of Chemoprophylaxis and Sporozoite Immunization With Plasmodium Falciparum NF135 Against Homologous and Heterologous Challenge Infection in Healthy Volunteers in the Netherlands [NCT03813108]		43 participants (Actual)	Interventional	2019-04-01	Terminated(stopped due to Subject withdrawals after temporal suspension of the trial (for personal, logistic reasons). At time of reinitiation the number of enrolled subjects did not meet the predefined threshold for continuation of the trial.)
Phase III Clinical Trials of Artemisinin-based Combination Therapy in Cameroon [NCT00297882]	Phase 3	816 participants (Actual)	Interventional	2006-07-31	Completed
[NCT00868465]		600 participants (Anticipated)	Interventional	2009-04-30	Completed
Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of the Congo: a Randomized Controlled Trial (TES2022) [NCT06076213]	Phase 4	1,408 participants (Anticipated)	Interventional	2023-05-01	Recruiting
Pharmacokinetics of Drugs Used to Treat Uncomplicated Malaria in Breastfeeding Mother-infant Pairs: An Observational Pharmacokinetic Study [NCT05676645]		30 participants (Anticipated)	Observational	2023-03-20	Recruiting
A Five-arm Trial Comparing Artesunate-amodiaquine and Artemether-lumefantrine-amodiaquine With or Without Single-dose Primaquine to Reduce P. Falciparum Transmission in Mali [NCT05550909]	Phase 2	100 participants (Actual)	Interventional	2022-10-17	Completed
Open Label Randomized Study Evaluating the in Vivo Efficacies of Artemether-lumefantrine and Dihydroartemisinin-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under Five Years of Age in Western Kenya [NCT05060198]		340 participants (Actual)	Interventional	2016-06-17	Completed
Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity [NCT05757167]	Phase 4	2,500 participants (Anticipated)	Interventional	2023-11-06	Recruiting
Evaluation of Dolutegravir Interactions With Artemether-Lumefantrine and Amodiaquine-Artesunate [NCT02242799]	Phase 1	46 participants (Actual)	Interventional	2015-06-30	Completed
Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Five Years After Wide Scale Use of the Drug in Tanzania. [NCT02089841]	Phase 4	140 participants (Actual)	Interventional	2012-05-31	Completed
In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Children: A Multisite, Open-label, Two-cohort Clinical Trial in Mozambique. [NCT02168569]	Phase 4	700 participants (Actual)	Interventional	2011-06-30	Completed
A Five-cohort, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine (SB252263) 300mg When Co-administered With the Artemisinin-based Combination Therapies (ACT) Artemether + Lumefantrine (AL) and Di [NCT02184637]	Phase 1	120 participants (Actual)	Interventional	2014-07-31	Completed
Efficacy and Safety of Artemether Lumefantrine Combination Therapy for the Treatment of Malaria Due to Plasmodium Ovale, Plasmodium Malariae, and Mixed Plasmodium Infections in Gabon [NCT00725777]		40 participants (Actual)	Interventional	2008-07-31	Completed
A Multi-center, Open-label, Randomized, Phase 4, Trial of Artemether-Lumefantrine and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Falciparum Malaria Parasitemia in Pregnant Women in Brazil [NCT01082731]	Phase 4	6 participants (Actual)	Interventional	2010-11-30	Terminated(stopped due to Extremely slow enrollment)
An Open-label, Randomized, Single-center, Parallel Group Study of the Effects of Artemether-lumefantrine (Coartem®) Atovaquone-proguanil (Malarone®) and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium F [NCT00444106]	Phase 4	265 participants (Actual)	Interventional	2007-05-31	Completed
Extended Duration Artemether-lumefantrine Treatment for Malaria in Children [NCT03453840]	Phase 4	305 participants (Actual)	Interventional	2018-02-19	Completed
Ethiopia In-vivo Efficacy Study 2009: Evaluating the Efficacy of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Infection and Either Artemether-lumefantrine or Chloroquine for P. Vivax Infection [NCT01052584]		354 participants (Actual)	Interventional	2009-10-31	Completed
Feasibility of Methylene Blue-based Combination Therapy in the Radical Treatment of Adult Patients With Plasmodium Vivax Malaria in Ethiopia: a Randomised Controlled Pilot Trial [NCT02696928]	Phase 2	0 participants (Actual)	Interventional	2016-04-30	Withdrawn(stopped due to Lack of ethical approval in Ethiopia)
Targeting Malaria High-risk Populations With Tailored Intervention Packages: A Study to Assess Feasibility and Effectiveness in Northern Namibia [NCT04094727]	Phase 4	3,302 participants (Actual)	Interventional	2019-10-31	Completed
A Randomized, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions of Orally Administered Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Adult Subjects [NCT02696954]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2016-11-18	Terminated
In Vivo Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria: an Open-randomised, Non-inferiority Clinical Trial in South Kivu, DR Congo [NCT02741024]	Phase 4	288 participants (Actual)	Interventional	2013-10-31	Completed
Lumefantrine Pharmacokinetics When Administered as a Fixed Dose Combination With Artemether in HIV Positive Patients on Lopinavir/Ritonavir [NCT00619944]	Phase 4	32 participants (Anticipated)	Interventional	2008-02-29	Completed
Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients [NCT00620438]	Phase 4	90 participants (Anticipated)	Interventional	2008-02-29	Active, not recruiting
Evaluation of the Effect of Targeted Mass Drug Administration and Reactive Case Detection on Malaria Transmission and Elimination in East Hararghe Zone, Oromia, Ethiopia [NCT04241705]		48,960 participants (Anticipated)	Interventional	2020-01-20	Recruiting
Study of Therapeutic Efficacy, Safety and Pharmacokinetic Interactions Between Artemether-lumefantrine and Nevirapine-based Antiretrovirals in HIV-infected Patients With Uncomplicated Falciparum-malaria in Muheza, Northeastern Tanzania [NCT00885287]	Phase 4	830 participants (Actual)	Interventional	2009-07-31	Completed
Programmatic Implementation of ACTs in Malawi: Safety and Effectiveness of Combination Therapies With Repeated Treatments for Uncomplicated P. Falciparum Malaria Over a Three-year Period [NCT01038063]	Phase 4	1,200 participants (Anticipated)	Interventional	2010-10-31	Recruiting
Phase III Comparative, Open-labelled, Randomised, Clinical Study to Assess a Fixed Dose of Oral Pyronaridine Artesunate Granule Formulation vs. Coartem® Crushed Tablets in Infants With Acute Uncomplicated Plasmodium Falciparum Malaria [NCT00541385]	Phase 3	535 participants (Actual)	Interventional	2007-10-31	Completed
Artemether-lumefantrine Vs Co-formulated Amodiaquine + Artesunate for the Treatment of Uncomplicated Falciparum Malaria: a Randomized Open-label Trial to Evaluate the Effectiveness of the Burkina Faso New Drug Policy [NCT01017770]	Phase 4	340 participants (Anticipated)	Interventional	2008-09-30	Completed
Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau [NCT04897919]	Phase 4	474 participants (Actual)	Interventional	2015-08-01	Completed
A Randomized Trial of Azithromycin + Artesunate v Artemether-lumefantrine in Uncomplicated Malaria in Tanzanian Children. [NCT00694694]	Phase 3	261 participants (Actual)	Interventional	2008-06-30	Completed
Pharmacokinetic Interactions Between Antiretroviral Agents, Lopinavir/Ritonavir and Efavirenz and Antimalarial Drug Combinations, Artesunate/Amodiaquine and Artemether/Lumefantrine. [NCT00697892]	Phase 1	38 participants (Actual)	Interventional	2005-07-31	Completed
An Open-label, Randomised, Controlled, Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of a Fixed Dose Triple Artemisinin-based Combination Therapy (TACT) Artemether-lumefantrine-amodiaquine Versus First-line Artemisinin-based Combi [NCT05951595]	Phase 3	1,440 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Nevirapine in HIV-infected Adults [NCT00790881]	Phase 4	36 participants (Anticipated)	Interventional	2008-10-31	Completed
Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria [NCT00852423]	Phase 3	3,428 participants (Actual)	Interventional	2010-06-30	Completed
A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria [NCT03939104]	Phase 3	1,368 participants (Anticipated)	Interventional	2021-06-30	Recruiting
A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria [NCT03923725]	Phase 3	3,240 participants (Anticipated)	Interventional	2020-09-01	Recruiting
Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children [NCT00393679]	Phase 3	4,112 participants (Actual)	Interventional	2007-07-31	Completed
[NCT01075945]	Phase 4	140 participants (Anticipated)	Interventional	2010-02-28	Recruiting
A Phase 1 Clinical Trial To Evaluate The Safety and Infectivity Of Direct Venus Inoculation of Aseptic, Purified, Cryopreserved Plasmodium Falciparum 7G8 And NF54 Challenge Strains (PfSPZ) in a Head-To-Head Comparative Study [NCT04203186]		0 participants (Actual)	Interventional	2020-03-31	Withdrawn(stopped due to Funding was lost due to the COVID19 Pandemic)
A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of Glucose-6-dehydrogenase Status in South-east Bangladesh [NCT02389374]	Phase 4	181 participants (Actual)	Interventional	2014-08-31	Completed
Comparison of Lumefantrine Concentrations Measured in Venous Plasma Versus in Dried Capillary Blood Spot Samples in Healthy Volunteers. [NCT02742285]	Phase 4	16 participants (Actual)	Interventional	2016-05-31	Completed
In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure [NCT02590627]	Phase 4	509 participants (Actual)	Interventional	2014-05-31	Completed
An Open-label, Single-center Study of the Effects of Co-artemether, Atovaquone-proguanil, and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Patients 12 Years of Age or Older. [NCT00386750]	Phase 4	265 participants	Interventional	2005-06-30	Terminated
A Randomized Open-Label Trial of the Efficacy of Artemether-Lumefantrine Suspension Compared With Artemether-Lumefantrine Tablets for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Less Than Five Years in Western Kenya [NCT00529867]	Phase 4	267 participants (Actual)	Interventional	2007-05-31	Completed
Interactions Between HIV and Malaria in African Children [NCT00527800]	Phase 3	351 participants (Actual)	Interventional	2007-08-31	Completed
Optimizing Malaria Treatment for HIV-Malaria Co-Infected Individuals by Addressing Drug Interactions Between Artemether-Lumefantrine and Efavirenz; a Randomized Controlled Trial [NCT04708496]	Phase 4	888 participants (Anticipated)	Interventional	2021-01-18	Recruiting
Assessment of Adherence to a 6-Dose Regimen of Coartem for Treatment of Uncomplicated Malaria in Children Under 5 Years in Tanzania [NCT00153491]		300 participants	Observational	2002-08-31	Completed
Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children [NCT00540202]	Phase 4	302 participants (Anticipated)	Interventional	2007-09-30	Recruiting
A Phase III Comparative (Double-blind, Double-dummy) Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Coartem® (Artemether Lumefantrine) in Children & Adult Patients With Falciparum Malaria [NCT00422084]	Phase 3	1,272 participants (Actual)	Interventional	2007-01-31	Completed
Treatment Outcomes for Non-malarial Febrile Illness in Children Aged 6-59 Months in Areas of Perennial Malaria Transmission [NCT01043744]		1,000 participants (Actual)	Interventional	2010-01-31	Completed
Efficacy and Safety of the Dispersible Formulation of Artemether-lumefantrine, Co-formulated Artesunate-amodiaquine and Co-formulated Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Machinga District, Mal [NCT01326754]		498 participants (Actual)	Interventional	2011-08-31	Completed
A Phase I, Partially Randomized, Open Label, Two-way, Two Period Cross-over Study to Investigate the Pharmacokinetic Interaction Between Etravirine or Darunavir/Rtv and Artemether/Lumefantrine at Steady-state in Healthy HIV-negative Subjects [NCT01876966]	Phase 1	33 participants (Actual)	Interventional	2011-03-31	Completed
THE OPTIMAL TIMING OF PRIMAQUINE TO PREVENT MALARIA TRANSMISSION AFTER ARTEMISININ-COMBINATION THERAPY [NCT01906788]	Phase 4	250 participants (Anticipated)	Interventional	2013-05-31	Recruiting
Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Pregnant Women in the Democratic Republic of Congo [NCT01916954]	Phase 3	96 participants (Actual)	Interventional	2013-07-31	Completed
A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of Low Dose Primaquine for Clearance of Gametocytes in Asymptomatic Individuals Infected With P. Falciparum in Burkina Faso [NCT01935882]	Phase 2/Phase 3	360 participants (Actual)	Interventional	2013-09-30	Completed
Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2) [NCT01939886]	Phase 3	219 participants (Actual)	Interventional	2013-04-30	Completed
Community-based Scheduled Screening and Treatment of Malaria in Pregnancy for Improved Maternal and Infant Health: a Cluster-randomized Trial in The Gambia, Burkina Faso and Benin [NCT01941264]		4,265 participants (Actual)	Interventional	2013-10-31	Completed
Efficacy and Bio-availability of Artemether-Lumefantrine Fixed Combination in Severely Malnourished Children Compared to Non-severely Malnourished Children [NCT01958905]		399 participants (Actual)	Interventional	2013-11-30	Completed
Adherence to Artemisinin-Based Combination Therapy (ACT) for the Treatment of Malaria in Sierra Leone [NCT01967472]		1,145 participants (Actual)	Interventional	2013-09-16	Completed
In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy in Kisumu County, Western Kenya [NCT01976780]	Phase 4	118 participants (Actual)	Interventional	2013-06-30	Completed
Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine Among Children With Uncomplicated P. Falciparum Malaria Five Years After Wide Scale Use of the Drug in Tanzania [NCT01998295]	Phase 4	45 participants (Actual)	Interventional	2012-05-31	Completed
Artemether-lumefantrine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi Malaria: a Randomized Open Label Trial in Sabah, Malaysia (CAN KNOW Trial) [NCT02001012]	Phase 3	123 participants (Actual)	Interventional	2014-01-31	Completed
An Open-label Randomized Controlled Trial to Evaluate the Effectiveness and Safety of a 3 Day Versus 5 Day Course of Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in Myanmar [NCT02020330]	Phase 3	150 participants (Actual)	Interventional	2013-11-25	Completed
A Randomized, Investigator-Blinded, Multicenter, Parallel-Group Study to Compare Efficacy, Safety and Tolerability of Arthemeter/ Lumefantrine Dispersible Tablet Formulation vs. Artemether/ Lumefantrine 6-Dose Crushed Tablet in the Treatment of Acute Unco [NCT00386763]	Phase 3	890 participants	Interventional	2006-08-31	Completed
Impact of a School-based Programme of Malaria Diagnosis and Treatment on School Attendance in Southern Malawi [NCT02213211]		3,667 participants (Actual)	Interventional	2014-04-30	Completed
Efficacy and Safety of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines in 2015 [NCT05958693]		82 participants (Actual)	Observational	2015-01-05	Completed
A Phase 2 Interventional, Multicenter, Randomized, Open-label Study in Three Age-descending Cohorts to Evaluate Efficacy, Safety and Tolerability of KAF156 and Lumefantrine-SDF Combination in the Treatment of Acute Uncomplicated Plasmodium Falciparum Mala [NCT04546633]	Phase 2	295 participants (Anticipated)	Interventional	2021-02-16	Recruiting
A Double Blind Randomized Controlled Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission [NCT01603251]	Phase 1/Phase 2	120 participants (Actual)	Interventional	2013-01-31	Completed
Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Lopinavir/Ritonavir in HIV-infected Adults [NCT00869700]	Phase 4	18 participants (Actual)	Interventional	2009-06-30	Completed
In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated Plasmodium Falciparum Malaria in Malawi, 2014 [NCT02637128]	Phase 4	452 participants (Actual)	Interventional	2014-03-31	Completed
Comparative Evaluation of the Safety and the Efficacy of Artemether + Lumefantrine (Coartem™) vs. Sulfadoxine + Pyrimethamine (SP) in Both HIV+ and HIV- Adults With Uncomplicated P. Falciparum Malaria in Zambia [NCT00304980]		3,000 participants	Interventional	2003-03-31	Terminated
A Randomized Study to Compare Artesunate + Amiodaquine Versus Artemether + Lumefantrine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During 2 Years in a Cohort in Senegal [NCT00540410]	Phase 4	366 participants (Actual)	Interventional	2007-09-30	Completed
Efficacy and Safety of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria Among Children in the North Region of Cameroon [NCT05340153]	Phase 4	184 participants (Anticipated)	Interventional	2022-04-11	Not yet recruiting
Phase 2 Proof of Concept Study of a Candidate Aminoquinoline Antimalarial (AQ-13) [NCT01614964]	Phase 2	66 participants (Actual)	Interventional	2013-08-31	Completed
Multicenter, Open-label, Single-arm Study to Evaluate the PK, Safety, Tolerability and Efficacy of a New Artemether:Lumefantrine (2.5 mg:30 mg) Dispersible Tablet in the Treatment of Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodi [NCT04300309]	Phase 2/Phase 3	28 participants (Actual)	Interventional	2020-12-21	Active, not recruiting
A Pilot, Double-blind, Randomized, Parallel-group, Placebo-controlled, Exploratory Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy ( [NCT04020653]	Phase 2	0 participants (Actual)	Interventional	2019-09-06	Withdrawn(stopped due to Considering the Thai FDA requirement, changes of Malaria cases in Thailand and EC recommendation, the decision to withdrawal the study was made.)
A Multi-centre, Randomised, Double-blind, Double Dummy Study Comparing the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Artemether-lumefantrine in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children and Adoles [NCT00344006]	Phase 3	1,395 participants (Actual)	Interventional	2006-06-30	Completed
Effectiveness of Artemether-Lumefantrine Treatment Provided by Community Health Worker Against Uncomplicated Malaria in Children Under 5 Years of Age in Tanzania [NCT00454961]	Phase 4	200 participants (Anticipated)	Interventional	2007-04-30	Completed
Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso [NCT04695197]	Phase 3	142 participants (Anticipated)	Interventional	2021-01-08	Recruiting
Longitudinal Comparison of Combination Antimalarial Therapies in Ugandan Children: Evaluation of Safety, Tolerability, and Efficacy [NCT00123552]	Phase 3	601 participants (Actual)	Interventional	2004-11-30	Completed
Characterization of Novel Molecular Tools for the Epidemiological Surveillance of Antimalarial Drug Resistance in Mali [NCT00127998]		1,011 participants	Interventional	2005-07-31	Completed
Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau. [NCT00426439]	Phase 4	300 participants (Anticipated)	Interventional	2006-12-31	Completed
Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine Versus Amodiaquine-Artesunate Coformulation in Uncomplicated Plasmodium Falciparum Malaria : an Open Randomized Study [NCT00460369]		240 participants (Actual)	Interventional	2007-04-30	Completed
Randomized Trial of the Safety and Effectiveness of Lapdap and Coartemether for Uncomplicated Malaria in Operational Settings [NCT00118794]	Phase 3	1,200 participants	Interventional	2004-09-30	Completed
Assessing and Monitoring the Efficacy of Sulfadoxine/ Pyrimethamine (SP) and the Combination of SP Plus Artesunate for Uncomplicated Malaria Infections Among Children [NCT00140361]	Phase 4	390 participants (Actual)	Interventional	2000-01-31	Completed
[NCT00406146]	Phase 3	0 participants	Interventional	2004-10-31	Active, not recruiting
Can Triple Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria, Delay Drug Resistance Development of Plasmodium Falciparum in Tanzania: a Randomized Three Arm Clinical Trial [NCT05764746]	Phase 2/Phase 3	384 participants (Anticipated)	Interventional	2023-04-01	Not yet recruiting
Open Label Study to Evaluate Combination Anti-malarial Therapy,in Terms of Efficacy, Prevalence of Gametocyte Carriage and Molecular Markers Associated With Sulfadoxine Pyrimethamine Resistance in Uncomplicated Plasmodium Falciparum [NCT00203801]		700 participants	Interventional	2002-01-31	Completed
Assessment of the Public Health Benefit of Artemisinine Based Combination Therapies for Uncomplicated Malaria Treatment in Mali [NCT00452907]	Phase 4	780 participants (Actual)	Interventional	2005-07-31	Completed
Efficacy and Safety of Artesunate-amodiaquine, Artemether-lumefantrine and Dihydroartemisinine-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of Congo: a Randomized Controlled Trial [NCT02940756]	Phase 4	1,615 participants (Actual)	Interventional	2017-03-15	Completed
Efficacy and Safety of Artesunate-amodiaquine (ASAQ) and Artemether-lumefantrine (AL) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Center Region of Cameroon [NCT04829695]	Phase 4	184 participants (Anticipated)	Interventional	2021-04-05	Not yet recruiting
An Open Randomised Trial of the Efficacy of Sulfadoxine-Pyrimethamine (SP), Amodiaquine + SP (AQ-SP), AQ + Artesunate (AQ-Art), Chlorproguanil-Dapsone + Art (CD-Art), and Lumefantrine-Artemether (LA) for Uncomplicated Malaria in Malawi [NCT00164710]	Phase 4	365 participants	Interventional	2005-04-30	Completed
Pharmacology of Artemisinin-Based Antimalarial Therapy Within the Context of Antiretroviral Therapy [NCT01728961]	Phase 4	19 participants (Anticipated)	Interventional	2012-02-29	Terminated(stopped due to Slow accrual and funding limitations.)
Pharmacokinetic Interactions Between Antiretroviral Agents, Lopinavir/Ritonavir and Efavirenz and Antimalarial Drug Combination, Artemether/Lumefantrine [NCT00266058]	Phase 1	33 participants (Actual)	Interventional	2005-12-31	Completed
Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine in People Living With HIV Attending Lagos University Teaching Hospital [NCT04531072]	Phase 4	20 participants (Actual)	Interventional	2018-09-18	Completed
Ethiopia Antimalarial in Vivo Efficacy Study 2012: Evaluating the Efficacy of Artemether-lumefantrine Alone Compared to Artemether-lumefantrine Plus Primaquine and Chloroquine Alone Compared to Chloroquine Plus Primaquine for Plasmodium Vivax Infection [NCT01680406]	Phase 4	398 participants (Actual)	Interventional	2012-10-31	Completed
[NCT00451139]	Phase 4	0 participants	Interventional		Completed
Treatment of Uncomplicated Childhood Malaria by an Artemisinin Derivative in Combination With Lumefantrine. Efficacy, Safety and Genotyping. [NCT00336375]	Phase 4	50 participants (Actual)	Interventional	2006-06-30	Completed
Artemether/Lumefantrine in the Treatment of Plasmodium Vivax Malaria in Eastern Sudan [NCT01625871]	Phase 3	38 participants (Actual)	Interventional	2011-09-30	Completed
An Individually Randomised Trial of Seasonal Malaria Chemoprevention Versus a Long-acting Artemisinin Combination Therapy for the Prevention of Malaria and Anaemia in Children Living in an Area of Extended Seasonal Transmission in Ghana. [NCT01651416]	Phase 4	2,400 participants (Actual)	Interventional	2012-07-31	Completed
Efficacy of Amodiaquine-Artesunate (ASAQ) and Artemether-Lumefantrine (AL) for the Treatment of Uncomplicated Falciparum Malaria in Nanoro, Burkina Faso [NCT01697787]	Phase 4	150 participants (Actual)	Interventional	2012-10-31	Completed
Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau. [NCT01704508]	Phase 4	346 participants (Actual)	Interventional	2012-11-30	Completed
Efficacy of Artesunate-amodiaquine, Dihydroartemisinin-piperaquine and Artemether-lumefantrine Combination Therapies for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Aged 6 to 59 Months in Maradi, Niger 2012-13 [NCT01755559]	Phase 4	663 participants (Actual)	Interventional	2013-06-30	Completed
Efficacy of Dried Leaf Artemisia (DLA) Versus Coartem (ACT): A Randomized Controlled Clinical Trial for Comparing DLA vs. ACT to Treat Malaria [NCT03199755]	Phase 2	0 participants (Actual)	Interventional	2018-08-20	Withdrawn(stopped due to Withdrawn in 2018 because clinicians did not follow protocols, issues with communication and also with tablet processing, nearby Ebola outbreak in 2018 (in the N Kivu area) confounded efforts.)
Phase III Study to Study the Clinical Response to ACT Fixed Dose Combination in 42 Days in Uncomplicated Malaria in Cameroon [NCT01845701]	Phase 3	720 participants (Actual)	Interventional	2010-03-31	Completed
A Comparative Assessment of the Effectiveness of Artemether Plus Lumefantrine Versus Artesunate Plus Amodiaquine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria [NCT00374205]	Phase 4	245 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to Interim analysis showed more LCFs in one of the treatment arms)
A Single Centre, Open Label, Pilot Phase Ib Study to Investigate Blood Stage Malaria Infection After Direct Venous Inoculation of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites (PfSPZ-DVI) in Malaria naïve Healthy Adult Volunteers [NCT04310085]	Phase 1	16 participants (Actual)	Interventional	2020-02-19	Completed
A Proof-of-concept Study to Assess the Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects [NCT02223871]	Phase 1	8 participants (Actual)	Interventional	2014-06-30	Completed
An Open-label, Randomized Multicenter Study to Investigate the Anti-parasitic Activity, Pharmacokinetic and Safety of IM SAR97276A With Oral ACTs as Positive Control in Children Presenting With Symptomatic Plasmodium Falciparum Uncomplicated Malaria [NCT01445938]	Phase 2	20 participants (Actual)	Interventional	2011-10-31	Terminated(stopped due to Data Monitoring Committee recommendation)
Cluster Randomized Trial of Malaria Seasonal IPTc Combined With Community Case Management in Saraya District, SE Senegal [NCT01449045]	Phase 3	4,554 participants (Actual)	Interventional	2011-07-31	Completed
Evaluation of Safety and Efficacy of Maytenus Senegalensis for the Treatment of Uncomplicated Malaria Episodes in Adult Patients as Compared to Artemether-lumefantrine [NCT04944966]	Phase 2	12 participants (Actual)	Interventional	2021-06-02	Completed
Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2) [NCT04778813]	Phase 4	1,050 participants (Anticipated)	Interventional	2021-06-01	Not yet recruiting
Ivermectin-artemisinin Combination Therapy for Eradication of Malaria [NCT05605925]	Phase 4	138 participants (Anticipated)	Interventional	2022-08-04	Recruiting
Comparative Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine in The Treatment of Acute Uncomplicated Malaria Among Children In South-West Nigeria [NCT05192265]	Phase 2/Phase 3	172 participants (Actual)	Interventional	2019-05-20	Completed
Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Uncomplicated Falciparum Malaria in Western Kenya [NCT02411994]	Phase 3	197 participants (Actual)	Interventional	2015-10-31	Completed
Epidemiology of Malaria in Malawi: Human Hosts and Parasites in Three Districts Part 2: Cross-sectional Surveillance (School-based Cohorts) [NCT04858087]		786 participants (Actual)	Observational	2015-03-24	Completed
A Randomized, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions of Orally Administered Artemether-lumefantrine and Amodiaquine in Healthy Adult Subjects [NCT04080895]	Phase 1	16 participants (Anticipated)	Interventional	2022-11-01	Recruiting
In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Children: A Multisite Open Label, Two-cohort Clinical Trial in Mozambique [NCT04370977]	Phase 4	630 participants (Actual)	Interventional	2018-03-21	Completed
The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana [NCT01459146]	Phase 4	345 participants (Anticipated)	Interventional	2010-12-31	Recruiting
Reducing the Burden of Malaria by Targeting Hotspots of Transmission and Improving Malaria Control Measures in the Highlands of Western Kenya: Simultaneous Rollout of Four Malaria Control Interventions and Evaluation by Cross-sectional Surveys [NCT01575613]		17,506 participants (Actual)	Interventional	2012-04-30	Completed
Artemether-Lumefantrine Clinical Effectiveness Study [NCT01599000]	Phase 4	159 participants (Actual)	Interventional	2011-03-31	Completed
Evaluating the Efficacy of Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Cruzeiro do Sul, Acre, Brazil [NCT02600767]		79 participants (Actual)	Interventional	2015-12-31	Completed
A Randomised, Single Blind, Placebo Controlled, Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Activity of Ruxolitinib When Co-administered With Artemether-lumefantrine in Healthy Participants [NCT04456634]	Phase 1	8 participants (Actual)	Interventional	2020-09-10	Completed
Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy Afric [NCT03510481]	Phase 1	478 participants (Actual)	Interventional	2018-05-14	Completed
Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of the Congo: a Randomized Controlled Trial [NCT04618523]	Phase 4	1,117 participants (Actual)	Interventional	2020-10-26	Completed
"Aiming at Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in an Era of Imminent Plasmodium Falciparum Resistance in Bagamoyo District, Tanzania - New Strategies With Old Tools" [NCT03241901]	Phase 4	280 participants (Actual)	Interventional	2017-07-27	Completed
An Open-label, Single-arm Study to Evaluate the Efficacy, Safety and PK of Artemether-lumefantrine Dispersible Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants <5 kg Body Weight [NCT01619878]	Phase 2/Phase 3	20 participants (Actual)	Interventional	2012-10-31	Completed
An Open-label Individually Randomised Controlled Trial to Assess the Efficacy of Artemether-lumefantrine Prophylaxis for Malaria Among Forest Goers in Cambodia [NCT04041973]		1,480 participants (Actual)	Interventional	2020-03-11	Completed
Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya [NCT01899820]	Phase 3	2,100 participants (Anticipated)	Interventional	2013-04-30	Active, not recruiting
A Phase I, Open-label, Fixed-sequence, Two-period, Crossover, Drug-drug Interaction Study to Evaluate the Effect of Multiple Doses of Ganaplacide and Lumefantrine Combination on the Pharmacokinetics of Midazolam, Repaglinide, Dextromethorphan, Metformin, [NCT05236530]	Phase 1	48 participants (Actual)	Interventional	2022-03-09	Completed
Efficacy of Artemether Lumefantrine (AL) and Dihydroartemisinin-Piperaquine (DHP) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Siaya and Bungoma Counties, Kenya [NCT04767191]	Phase 4	400 participants (Actual)	Interventional	2021-03-15	Completed
Efficacy and Safety of Artemether Lumefantrine for the Treatment of Uncomplicated Malaria in Tanzania [NCT03387631]		344 participants (Actual)	Observational [Patient Registry]	2016-04-30	Completed
Field Study of the Pharmacokinetics and Pharmacodynamics of Artemisinin-based Combination Therapy for Gametocyte Clearance and Post-treatment Chemoprotection in Zambian Children With Uncomplicated Falciparum Malaria [NCT04009343]	Phase 2/Phase 3	182 participants (Anticipated)	Interventional	2019-06-19	Active, not recruiting
Assessment of Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa [NCT02974348]	Phase 3	300 participants (Actual)	Interventional	2013-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00297882 (2) [back to overview]	Cure Rate on Day 28
NCT00297882 (2) [back to overview]	Cure Rate Day 14
NCT00422084 (8) [back to overview]	Proportion of Patients With Parasite Clearance at Day 1, 2 and 3
NCT00422084 (8) [back to overview]	Percentage of Patients With Fever Clearance at Day 1, 2 and 3
NCT00422084 (8) [back to overview]	Crude ACPR (Non-PCR Corrected ACPR) on Day 14 and Day 28
NCT00422084 (8) [back to overview]	Adverse Events and Clinically Significant Laboratory Results
NCT00422084 (8) [back to overview]	PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28
NCT00422084 (8) [back to overview]	PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 14
NCT00422084 (8) [back to overview]	Parasite Clearance Time
NCT00422084 (8) [back to overview]	Fever Clearance Time
NCT00444106 (4) [back to overview]	Relationship Between Changes in Auditory Function and Treatment Groups
NCT00444106 (4) [back to overview]	Efficacy of Polymerase Chain Reaction (PCR) Adjusted Malaria Cure Rates of the Three Treatment Regimens at Days 14, 28 and 42
NCT00444106 (4) [back to overview]	Auditory Changes Following 3 Days of Treatment at Days 3, 7, 28, and 42 Days as Assessed by Pure Tone Thresholds Assessments (a Type of Hearing Test)
NCT00444106 (4) [back to overview]	Percentage of Participants With Auditory Abnormalities at Day 7 Assessed by Auditory Brainstem Response (ABR) Wave III Latency Changes on Day 7(a Type of Hearing Test)
NCT00541385 (8) [back to overview]	Percentage of Participants With PCR-Corrected ACPR on Day 28
NCT00541385 (8) [back to overview]	Percentage of Participants With PCR-Corrected ACPR on Day 14
NCT00541385 (8) [back to overview]	Parasite Clearance Time
NCT00541385 (8) [back to overview]	Fever Clearance Time
NCT00541385 (8) [back to overview]	Proportion of Subjects With Fever Cleared on Days 1, 2, and 3
NCT00541385 (8) [back to overview]	Number of Subjects With ≥1 Adverse Event
NCT00541385 (8) [back to overview]	Proportion of Subjects With Cleared Parasites on Days 1, 2, and 3
NCT00541385 (8) [back to overview]	Crude ACPR (Non-PCR Corrected ACPR) (Crude Cure Rate) on Day 14 and Day 28
NCT00677833 (19) [back to overview]	Percentage of Participants With PCR-corrected ACPR at Day 28 in Per-Protocol (PP) Population
NCT00677833 (19) [back to overview]	Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitologic Response (ACPR) at Day 28 in the Modified Intent-to-treat (mITT) Population
NCT00677833 (19) [back to overview]	Time to Recurrence of Parasitemia
NCT00677833 (19) [back to overview]	Change From Nadir Hemoglobin Level at Days 14, 28, and 42
NCT00677833 (19) [back to overview]	Percentage of Participants With Gametocytologic Response
NCT00677833 (19) [back to overview]	Percentage of Participants With Late Clinical Failure (LCF) in the mITT Population (PCR-corrected)
NCT00677833 (19) [back to overview]	Percentage of Participants With Late Parasitologic Failure (LPF) in the mITT Population (PCR-corrected)
NCT00677833 (19) [back to overview]	Percentage of Participants With LCF in PP Population (PCR-corrected)
NCT00677833 (19) [back to overview]	Fever Clearance Time
NCT00677833 (19) [back to overview]	Percentage of Participants With LPF in PP Population (PCR-corrected)
NCT00677833 (19) [back to overview]	Percentage of Participants With PCR-uncorrected ACPR in the mITT Population
NCT00677833 (19) [back to overview]	Percentage of Participants With PCR-corrected ACPR in PP Population
NCT00677833 (19) [back to overview]	Percentage of Participants With PCR-corrected ACPR in the mITT Population
NCT00677833 (19) [back to overview]	Percentage of Participants With PCR-uncorrected ACPR in PP Population
NCT00677833 (19) [back to overview]	Percentage of Participants With Asexual Parasitologic Response (PCR-corrected)
NCT00677833 (19) [back to overview]	Asexual Plasmodium Falciparum Parasite Clearance Time
NCT00677833 (19) [back to overview]	Nadir Hemoglobin Level
NCT00677833 (19) [back to overview]	Percentage of Participants With Early Treatment Failure (ETF) in the mITT Population (PCR-corrected)
NCT00677833 (19) [back to overview]	Percentage of Participants With ETF in PP Population (PCR-corrected)
NCT01256658 (22) [back to overview]	Number of Asymptomatic Carriers With Increase in Hemoglobin Levels by at Least 0.5 g/dL From Day 1 to Day 28 of Community Screening Campaign 1 (CSC1) in Infants and Children (>6 Months and <5 Years)- Cluster Data
NCT01256658 (22) [back to overview]	Microscopy Confirmed Asymptomatic Carriers of P. Falciparum at Community Screening Campaign 4 (CSC4) (Per Cluster)
NCT01256658 (22) [back to overview]	Microscopy-confirmed Gametocyte Carriers at Community Screening Campaign 4 (CSC4) (Per Cluster)
NCT01256658 (22) [back to overview]	Number of Asymptomatic Carriers With Increase in Hemoglobin Levels by at Least 0.5 g/dL From Community Screening Campaign 1 (CSC1) Infants and Children (>6 Months and <5 Years)- Individual Data
NCT01256658 (22) [back to overview]	Anemia Status Based on Community Screening Campaign 1 (CSC1)/Day 1 in Infants and Children (>6 Months and <5 Years)
NCT01256658 (22) [back to overview]	Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Infants and Children (<5 Years) in Post Community Screening Campaign (CSC) at Month 12 (Per Cluster)
NCT01256658 (22) [back to overview]	Anemia Status Based on Community Screening Campaign 4 (CSC4)/Day 1 in Infants and Children (>6 Months and <5 Years)
NCT01256658 (22) [back to overview]	Change in Hemoglobin Level (g/dL) From Community Screening Campaign 1 (CSC1)/Day 1 to CSC1/Day 28 in Infants and Children (>6 Months and <5 Years) for Asymptomatic Carriers at CSC1
NCT01256658 (22) [back to overview]	Change in Hemoglobin Level (g/dL) From Community Screening Campaign 1(CSC1)/Day 1 to Community Screening Campaign 4 (CSC4)/Day 1 (Per Cluster)
NCT01256658 (22) [back to overview]	Change in Hemoglobin Level (g/dL) in Asymptomatic Carriers >6 Months of Age (Per Cluster)
NCT01256658 (22) [back to overview]	Cumulative Number of Subjects With Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL From Week 1 to Week 50
NCT01256658 (22) [back to overview]	Hemoglobin Level (g/dL) in Community Screening Campaign 1 (CSC1)/Day 1 and CSC4/Day 1 by Study Arm and Age Group (Per Cluster)
NCT01256658 (22) [back to overview]	Mean Number of Microscopy-confirmed Gametocyte Carriers at Day 1 of Community Screening Campaign 1,2,3,4 (CSC1, CSC2, CSC3 and CSC4) (Per Cluster)
NCT01256658 (22) [back to overview]	Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Post Community Screening Campaign (CSC)
NCT01256658 (22) [back to overview]	Mean of Microscopy-confirmed Asymptomatic Carriers From Community Screening Campaigns 1, 2, 3 and 4 (CSC1, CSC2, CSC3 and CSC4) (Per Cluster)
NCT01256658 (22) [back to overview]	Number of Asymptomatic Carriers With Complicated and Uncomplicated Episodes Combined
NCT01256658 (22) [back to overview]	Number of Microscopy and qRT-PCR-confirmed Gametocyte Carriers at Community Screening Campaign 4 (CSC4)
NCT01256658 (22) [back to overview]	Number of Participants (Infants and Children (> 6 Months and < 5 Years)) With Hospitalizations, Severe Malaria Episodes or Death Post Community Screening Campaign (CSC)
NCT01256658 (22) [back to overview]	Number of Participants With Hospitalizations, Severe Malaria Episodes or Death Post Community Screening Campaign (CSC)
NCT01256658 (22) [back to overview]	Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000) in Asymptomatic Carriers at Any Time of Diagnosis (Per Cluster)
NCT01256658 (22) [back to overview]	Percentage of COA566-treated Microscopy-confirmed Asymptomatic Carriers at Community Screening Campaign 1, 2 and 3 (CSC1, CSC2 and CSC3) With Parasitological Cure Rate at Day 7
NCT01256658 (22) [back to overview]	Percentage of Microscopy-confirmed Gametocyte Carriers Treated With COA566 for Asymptomatic Carriers
NCT01619878 (9) [back to overview]	Time to Parasite Clearance (PCT)
NCT01619878 (9) [back to overview]	Time to Gametocyte Clearance (GCT)
NCT01619878 (9) [back to overview]	Time to Fever Clearance (FCT)
NCT01619878 (9) [back to overview]	Polymerase Chain Reaction (PCR) Corrected 28 Day Parasitological Cure Rate
NCT01619878 (9) [back to overview]	Percent Change of Parasite Count From Baseline at 24 Hours
NCT01619878 (9) [back to overview]	Number of Participants With Parasitaemia at 72 Hours After Treatment Initiation Greater Than or Equal to 25 Percent of Count at Baseline
NCT01619878 (9) [back to overview]	Number of Participants With Parasitaemia at 48 Hours After Treatment Initiation Greater Than at Baseline
NCT01619878 (9) [back to overview]	Polymerase Chain Reaction (PCR) Corrected Parasitological Cure Rate at Day 14 and 42
NCT01619878 (9) [back to overview]	Number of Participants With Parasitological Uncorrected Cure Rate at Day 3, 7, 14, 28 and 42
NCT02223871 (9) [back to overview]	Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a New Approach
NCT02223871 (9) [back to overview]	Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a Standardized Approach
NCT02223871 (9) [back to overview]	Maximum Plasma Concentration (Cmax) of ACT-451840
NCT02223871 (9) [back to overview]	Terminal Half-life [t(1/2)]
NCT02223871 (9) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) of ACT-451840
NCT02223871 (9) [back to overview]	Areas Under the Plasma Concentration-time Curve of ACT-451840
NCT02223871 (9) [back to overview]	Change From Baseline in Blood Pressure to End of Study (EOS)
NCT02223871 (9) [back to overview]	Change From Baseline in Body Temperature up to End of Study (EOS)
NCT02223871 (9) [back to overview]	Change From Baseline in Respiratory Rate to End of Study (EOS)
NCT02389374 (9) [back to overview]	Proportion of Patients With Fever on Day 2 After Treatment
NCT02389374 (9) [back to overview]	Proportion of Patients Adhering to 14 Days of Primaquine Treatment in the Vivax Cohort as Measured by Pill Count
NCT02389374 (9) [back to overview]	Proportion of Patients Receiving Blood Transfusion and With Severe Anaemia (Hb<7g/dl)
NCT02389374 (9) [back to overview]	Proportion of Patients With Anaemia Less Than 8g/dl on Day 2
NCT02389374 (9) [back to overview]	Proportion of Patients With Any Parasitemia on Day 3 After Treatment
NCT02389374 (9) [back to overview]	Fractional Change in Hb Between Baseline and Day 9 and 16
NCT02389374 (9) [back to overview]	Recurrence of Parasitaemia Within 16 Days of Follow up
NCT02389374 (9) [back to overview]	The Distribution of G6PD Activity Measured in U/gHb Among All Malaria Patients
NCT02389374 (9) [back to overview]	The Proportion of Adverse and Serious Adverse Events Following Unsupervised Primaquine Treatment
NCT02600767 (1) [back to overview]	Absence of Malaria Parasites in Blood.
NCT03167242 (13) [back to overview]	PK Run-in: Area Under the Blood Concentration-time Curve Over the Last 24 Hours After Treatment Dose (AUC0-24h) of KAF156
NCT03167242 (13) [back to overview]	PK Run-in, Part A and Part B: Parasite Clearance Time (PCT)
NCT03167242 (13) [back to overview]	Part A and Part B: Area Under the Blood Concentration-time Curve Over the Last 24 Hours After Last Treatment Dose (AUC0-24h) of KAF156
NCT03167242 (13) [back to overview]	PK Run-in and Part A: Elimination Half-life (T½) of KAF156
NCT03167242 (13) [back to overview]	Part A and Part B: Number of Participants With Reinfection Events
NCT03167242 (13) [back to overview]	Part A and Part B: Number of Participants With Recrudescence Events
NCT03167242 (13) [back to overview]	Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29
NCT03167242 (13) [back to overview]	Part A and Part B: Maximum Peak Observed Concentration (Cmax) of KAF156
NCT03167242 (13) [back to overview]	PK Run-in and Part A (Cohorts 1 and 2): Time to Reach Maximum Blood Concentrations (Tmax) of KAF156
NCT03167242 (13) [back to overview]	Part A and Part B: Fever Clearance Time (FCT)
NCT03167242 (13) [back to overview]	PK Run-in, Part A and Part B: Number of Participants With Parasitaemia
NCT03167242 (13) [back to overview]	Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Uncorrected Adequate Clinical and Parasitological Response (ACPR)
NCT03167242 (13) [back to overview]	Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR)
NCT03334747 (14) [back to overview]	Tmax
NCT03334747 (14) [back to overview]	Tmax
NCT03334747 (14) [back to overview]	Time to Recrudescence and Reinfection at Study Day 29
NCT03334747 (14) [back to overview]	Time to Recrudescence and Reinfection at Study Day 29
NCT03334747 (14) [back to overview]	Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected and Uncorrected Adequate Clinical and Parasitological Response (ACPR) at Day 15 and Day 29
NCT03334747 (14) [back to overview]	Maximum Peak Observed Concentration (Cmax)
NCT03334747 (14) [back to overview]	Maximum Peak Observed Concentration (Cmax)
NCT03334747 (14) [back to overview]	Half-life (T^1/2)
NCT03334747 (14) [back to overview]	Parasite Clearance Time (PCT)
NCT03334747 (14) [back to overview]	Number of Participants With at Least 2 CTCAE Grades Increase From Baseline in Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST)
NCT03334747 (14) [back to overview]	Half-life (T^1/2)
NCT03334747 (14) [back to overview]	Fever Clearance Time (FCT)
NCT03334747 (14) [back to overview]	AUC0-24
NCT03334747 (14) [back to overview]	AUC0-24
NCT03510481 (2) [back to overview]	Number of Participants With Local and Systemic Adverse Events in Year One
NCT03510481 (2) [back to overview]	Number of Participants With Local and Systemic Adverse Events in Year Two
NCT03813108 (5) [back to overview]	Break Through Infections
NCT03813108 (5) [back to overview]	Magnitude of Adverse Events After NF135.C10 CPS Immunization
NCT03813108 (5) [back to overview]	Break Through Infections
NCT03813108 (5) [back to overview]	Frequency of Adverse Events After NF135.C10 CPS Immunization
NCT03813108 (5) [back to overview]	Time to Parasitemia
NCT04222088 (4) [back to overview]	Adequate Clinical and Parasitological Response (ACPR)
NCT04222088 (4) [back to overview]	Late Parasitological Failure (LPF)
NCT04222088 (4) [back to overview]	Late Clinical Failure (LCF)
NCT04222088 (4) [back to overview]	Early Treatment Failure (ETF)
NCT04310085 (9) [back to overview]	Parasitaemia at First Dose of Treatment With Riamet® (Cohorts 1 and 2)
NCT04310085 (9) [back to overview]	Incidence of Positive PCR and Parasitaemia of ≥5000 Parasites Per mL Blood.
NCT04310085 (9) [back to overview]	Time to First Dose of Treatment With Artemether-lumefantrine (Riamet®) (Cohorts 1 and 2)
NCT04310085 (9) [back to overview]	Time to First PCR Positivity.
NCT04310085 (9) [back to overview]	Parasitaemia at the Time Parasitaemia ≥5000 Parasites Per mL Blood (Cohorts 1 and 2)
NCT04310085 (9) [back to overview]	Change in Malaria Clinical Score From PfSPZ-DVI Challenge Until Parasite Clearance.
NCT04310085 (9) [back to overview]	Time to Parasitaemia of ≥5000 Parasites Per mL Blood (Cohorts 1 and 2)
NCT04310085 (9) [back to overview]	Incidence and Severity of Observed or Self-reported Adverse Events (AEs) Considered PfSPZ-DVI Challenge Inoculum-related.
NCT04310085 (9) [back to overview]	Parasitaemia at First PCR Positivity
NCT04456634 (5) [back to overview]	AUECt of pSTAT3 Inhibition
NCT04456634 (5) [back to overview]	Number of Participants With Changes in Heart Rate
NCT04456634 (5) [back to overview]	Number of Participants With Changes of Systolic and Diastolic Blood Pressure
NCT04456634 (5) [back to overview]	Number of Participants With ECG Changes
NCT04456634 (5) [back to overview]	Number of Participant With Treatment-Related Adverse Events as Assessed by CTCAE V4.03, All of Observed and Self-reported AEs Affected, by Treatment Regimen.

Cure Rate on Day 28

To evaluate the safety and antimalarial efficacy of two drug combinations: Artemether-Lumefantrine (AL) and Amodiaquine-Artesunate (AQ - AS) in Camaroonian patients in Mutengene, Bangolan and Garoua (NCT00297882)
Timeframe: Day 0 - 28

Intervention	Participants (Count of Participants)
1 Artemether-Lumefantrine AL	197
2 Amodiaquine-Artesunate AQ-AS	603

Intervention	percentage of subjects (Number)
	Clearance rate (%) at Day 1 (24h after first dose)	Clearance rate (%) at Day 2 (48h after first dose)	Clearance rate (%) at Day 3 (72h after first dose)
AL Group	52.8	97.2	99.7
PA Group	68.1	98.1	99.5

Intervention	percentage of subjects (Number)
	Cure rate (%) at Day 14	Cure rate (%) at Day 28
AL Group	100	97.2
PA Group	100	98.9

Intervention	Participants (Count of Participants)
	Nr subj. with ≥1 AE	Nr subj. with ≥1 treatment-related AE	Nr subj. with ≥1 SAE	Nr pat with ≥1 treatment-related SAE	Nr subj. with ≥1 severe or life-threatening AE	Nr subj. with ≥1 AE leading to death	Nr subj. ≥1 AE leading to drug discontinuation	Nr subj. with ≥1 AE leading to study withdrawal
AL Group	241	123	2	0	5	0	5	6
PA Group	509	275	3	0	10	0	16	19

Intervention	ms (Mean)
	Baseline Right Ear	Change from baseline to Day 7 Right Ear	Baseline Left Ear	Change from baseline to Day 7 Left Ear
Artemether-lumefantrine (Coartem)	3.86	0.01	3.85	0.01
Artesunate-mefloquine	3.86	-0.04	3.82	-0.03
Atovaquone-proguanil (Malarone)	3.89	-0.01	3.88	-0.01

Intervention	Percentage of Participants (Number)
	Day 14	Day 28	Day 42
Artemether-lumefantrine (Coartem)	99.4	98.7	97.5
Artesunate-mefloquine	98.1	98.1	98.1
Atovaquone-proguanil (Malarone)	100.0	98.1	98.1

Intervention	dB (Mean)
	Baseline Right Ear	Change from baseline to Day 3 Right Ear	Change from baseline to Day 7 Right Ear	Change from baseline to Day 28 Right Ear	Change from baseline to Day 42 Right Ear	Baseline Left Ear	Change from baseline to Day 3 Left Ear	Change from baseline to Day 7 Left Ear	Change from baseline to Day 28 Left Ear	Change from baseline to Day 42 Left Ear
Artemether-lumefantrine	12.2	-2.5	-2.2	-2.7	-3.0	11.4	-1.2	-1.7	-2.0	-1.5
Artesunate-mefloquine	12.7	-1.9	-2.6	-3.6	-3.1	12.5	-1.2	-1.4	-2.5	-3.0
Atovaquone-proguanil (Malarone)	12.0	-2.4	-2.6	-2.6	-3.3	11.3	-1.5	-1.3	-1.8	-2.1

Intervention	percentage of subjects (Number)
	Percentage of Participants with fever clearance at Day 1 (24h after first dose)	Percentage of Participants with fever clearance at Day 2 (48h after first dose)	Percentage of Participants with fever clearance at Day 3 (48h after first dose)
AL Group	81.0	96.8	98.4
PA Group	87.1	98.5	99.6

Intervention	percentage of subjects (Number)
	Percentage of Participants with parasite clearance at Day 1 (24h after first dose)	Percentage of Participants with parasite clearance at Day 2 (48h after first dose)	Percentage of Participants with parasite clearance at Day 3 (72h after first dose)
AL Group	43.7	95.2	98.8
PA Group	49.9	95.5	97.0

Intervention	percentage of subjects (Number)
	Percentage of Participants with ACPR at Day 14	Percentage of Participants with ACPR at Day 28
AL Group	100	89.2
PA Group	100	90.2

Intervention	Percentage of participants (Number)
Cohort 2: Azithromycin + Chloroquine	93.08
Cohort 2: Artemether + Lumefantrine	99.16

Intervention	hours (Median)
PA Group	23.9
AL Group	24.0

Intervention	hours (Median)
PA Group	7.9
AL Group	8.0

Intervention	hours (Median)
PA Group	24.1
AL Group	24.2

Intervention	Percentage of participants (Number)
Cohort 2: Azithromycin + Chloroquine	89.27
Cohort 2: Artemether + Lumefantrine	98.37

Intervention	g/dL (Mean)
	Change at Day 14 (n=122, 127)	Change at Day 28 (n=122, 127)	Change at Day 42 (n=122, 128)
Cohort 2: Artemether + Lumefantrine	0.44	0.96	1.14
Cohort 2: Azithromycin + Chloroquine	0.52	1.15	1.29

Intervention	Percentage of participants (Number)
	Day 7 (n=122, 129)	Day 14 (n=122, 130)	Day 21 (n=122, 130)	Day 28 (n=122, 130)	Day 35 (n=122, 130)	Day 42 (n=122, 130)
Cohort 2: Artemether + Lumefantrine	91.47	91.54	93.08	93.08	92.31	91.54
Cohort 2: Azithromycin + Chloroquine	81.97	81.15	80.33	81.97	81.97	80.33

Intervention	Percentage of participants (Number)
	Day 7	Day 14	Day 21	Day 28	Day 35	Day 42
Cohort 2: Artemether + Lumefantrine	0	0	0	0	0	0
Cohort 2: Azithromycin + Chloroquine	0	0	0	0	0	0

Intervention	Hours (Median)
Cohort 2: Azithromycin + Chloroquine	24.000
Cohort 2: Artemether + Lumefantrine	24.000

Intervention	Percentage of participants (Number)
	Day 7 (n=120, 128)	Day 14 (n=120, 127)	Day 21 (n=120, 128)	Day 28 (n=120, 127)	Day 35 (n=120, 128)	Day 42 (n=120, 127)
Cohort 2: Artemether + Lumefantrine	99.22	99.21	98.44	98.43	96.88	96.85
Cohort 2: Azithromycin + Chloroquine	93.33	91.67	90.83	89.17	89.17	88.33

Intervention	Hours (Median)
Cohort 2: Azithromycin + Chloroquine	48.000
Cohort 2: Artemether + Lumefantrine	24.000

Intervention	grams per deciliter (g/dL) (Mean)
Cohort 2: Azithromycin + Chloroquine	9.63
Cohort 2: Artemether + Lumefantrine	9.82

Intervention	Percentage of participants (Number)
Cohort 2: Azithromycin + Chloroquine	5.83
Cohort 2: Artemether + Lumefantrine	0.79

Intervention	Percentage of participants (Number)
Cohort 2: Azithromycin + Chloroquine	1.75
Cohort 2: Artemether + Lumefantrine	0

lumefantrine

Description

Cross-References

Synonyms (104)

Research Excerpts

Overview

Effects

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (4)

Protein Targets (38)

Potency Measurements

Inhibition Measurements

Biological Processes (67)

Molecular Functions (29)

Ceullar Components (26)

Bioassays (149)

Research

Studies (471)

Market Indicators

Research Demand Index: 73.20

Study Types

Clinical Trials (169)

Trial Overview

Trial Outcomes

Cure Rate on Day 28

Cure Rate Day 14

Proportion of Patients With Parasite Clearance at Day 1, 2 and 3

Percentage of Patients With Fever Clearance at Day 1, 2 and 3

Crude ACPR (Non-PCR Corrected ACPR) on Day 14 and Day 28

Adverse Events and Clinically Significant Laboratory Results

PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28

PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 14

Parasite Clearance Time

Fever Clearance Time

Relationship Between Changes in Auditory Function and Treatment Groups

Efficacy of Polymerase Chain Reaction (PCR) Adjusted Malaria Cure Rates of the Three Treatment Regimens at Days 14, 28 and 42

Auditory Changes Following 3 Days of Treatment at Days 3, 7, 28, and 42 Days as Assessed by Pure Tone Thresholds Assessments (a Type of Hearing Test)

Percentage of Participants With Auditory Abnormalities at Day 7 Assessed by Auditory Brainstem Response (ABR) Wave III Latency Changes on Day 7(a Type of Hearing Test)

Percentage of Participants With PCR-Corrected ACPR on Day 28

Percentage of Participants With PCR-Corrected ACPR on Day 14

Parasite Clearance Time

Fever Clearance Time

Proportion of Subjects With Fever Cleared on Days 1, 2, and 3

Number of Subjects With ≥1 Adverse Event

Proportion of Subjects With Cleared Parasites on Days 1, 2, and 3

Crude ACPR (Non-PCR Corrected ACPR) (Crude Cure Rate) on Day 14 and Day 28

Percentage of Participants With PCR-corrected ACPR at Day 28 in Per-Protocol (PP) Population

Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitologic Response (ACPR) at Day 28 in the Modified Intent-to-treat (mITT) Population

Time to Recurrence of Parasitemia

Change From Nadir Hemoglobin Level at Days 14, 28, and 42

Percentage of Participants With Gametocytologic Response

Percentage of Participants With Late Clinical Failure (LCF) in the mITT Population (PCR-corrected)

Percentage of Participants With Late Parasitologic Failure (LPF) in the mITT Population (PCR-corrected)

Percentage of Participants With LCF in PP Population (PCR-corrected)

Fever Clearance Time

Percentage of Participants With LPF in PP Population (PCR-corrected)

Percentage of Participants With PCR-uncorrected ACPR in the mITT Population

Percentage of Participants With PCR-corrected ACPR in PP Population

Percentage of Participants With PCR-corrected ACPR in the mITT Population

Percentage of Participants With PCR-uncorrected ACPR in PP Population

Percentage of Participants With Asexual Parasitologic Response (PCR-corrected)

Asexual Plasmodium Falciparum Parasite Clearance Time

Nadir Hemoglobin Level

Percentage of Participants With Early Treatment Failure (ETF) in the mITT Population (PCR-corrected)

Percentage of Participants With ETF in PP Population (PCR-corrected)

Number of Asymptomatic Carriers With Increase in Hemoglobin Levels by at Least 0.5 g/dL From Day 1 to Day 28 of Community Screening Campaign 1 (CSC1) in Infants and Children (>6 Months and <5 Years)- Cluster Data

Microscopy Confirmed Asymptomatic Carriers of P. Falciparum at Community Screening Campaign 4 (CSC4) (Per Cluster)

Microscopy-confirmed Gametocyte Carriers at Community Screening Campaign 4 (CSC4) (Per Cluster)

Number of Asymptomatic Carriers With Increase in Hemoglobin Levels by at Least 0.5 g/dL From Community Screening Campaign 1 (CSC1) Infants and Children (>6 Months and <5 Years)- Individual Data

Anemia Status Based on Community Screening Campaign 1 (CSC1)/Day 1 in Infants and Children (>6 Months and <5 Years)

Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Infants and Children (<5 Years) in Post Community Screening Campaign (CSC) at Month 12 (Per Cluster)

Anemia Status Based on Community Screening Campaign 4 (CSC4)/Day 1 in Infants and Children (>6 Months and <5 Years)

Change in Hemoglobin Level (g/dL) From Community Screening Campaign 1 (CSC1)/Day 1 to CSC1/Day 28 in Infants and Children (>6 Months and <5 Years) for Asymptomatic Carriers at CSC1

Change in Hemoglobin Level (g/dL) From Community Screening Campaign 1(CSC1)/Day 1 to Community Screening Campaign 4 (CSC4)/Day 1 (Per Cluster)

Change in Hemoglobin Level (g/dL) in Asymptomatic Carriers >6 Months of Age (Per Cluster)

Intervention	participants (Number)
	CSC1/Day 1 Severe	CSC1/Day 1 Moderate	CSC1/Day 1 Mild	CSC1/Day 1 No symptoms
Control	1	36	195	116
Intervention	3	80	458	278

Intervention	participants (Number)
	CSC4/Day 1 Severe	CSC4/Day 1 Moderate	CSC4/Day 1 Mild	CSC4/Day 1 No
Control	1	9	117	194
Intervention	1	29	349	448

Intervention	g/dL (Mean)
	CSC1/Day 1 (n=432 ; 179 )	CSC1/Day 28 (n=406 ; 174 )
Control	9.67	10.17
Intervention	9.78	10.95

Intervention	g/dL (Mean)
	CSC1/Day 1 (n= 819, 827)	CSC4/Day 1 (n= 348,321)
Control	10.04	11.13
Intervention	10.24	10.99

Intervention	g/dL (Mean)
	Day 1 (n = 2387, 2116)	Day 28 (n = 1136, 1091)
Control	12.06	11.86
Intervention	11.81	12.33

Intervention	participants (Number)
	Week (1-2) n at risk= 2397, 1138	Week (3-4) n at risk= 2396, 1133	Week (5-6) n at risk= 2391, 1129	Week (7-8) n at risk= 2390, 1124	Week (9-10) n at risk= 2390, 1123	Week (11-12) n at risk= 2390, 1121	Week (13-14) n at risk= 2390, 1103	Week (15-16) n at risk= 2390, 1102	Week (17-18) n at risk= 2390, 1102	Week (19-20) n at risk= 2390, 1102	Week (21-22) n at risk= 2337, 1083	Week (23-24) n at risk= 2311, 1077	Week (25-26) n at risk= 2246, 1063	Week (27-28) n at risk= 2148, 1041	Week (29-30) n at risk= 2047, 1020	Week (31-32) n at risk= 1979, 996	Week (33-34) n at risk= 1931, 979	Week (35-36) n at risk= 1894, 968	Week (37-38) n at risk= 1868, 956	Week (39-40) n at risk= 1837, 935	Week (41-42) n at risk= 1816, 927	Week (43-44) n at risk= 1805, 920	Week (45-46) n at risk= 1785, 913	Week (47-48) n at risk= 1773, 910	Week (49-50) n at risk= 1758, 904
Control	4	8	12	13	15	17	18	18	18	20	24	38	59	79	98	114	121	130	144	149	154	158	159	161	161
Intervention	1	3	4	4	4	4	4	4	4	7	30	92	188	287	347	391	421	440	460	477	483	486	490	492	493

Intervention	g/dL (Mean)
	CSC1 5- 9 years (n= 899, 431)	CSC4 5 - 9 years (n= 900, 396)	CSC1 10 - 14 years (n= 873, 380)	CSC4 10 - 14 years (n= 837, 359)	CSC1 >= 15 years (n= 2904, 1279)	CSC4 >= 15 years (n= 2760, 1136)
Control	11.59	12.13	12.71	12.72	13.49	13.42
Intervention	11.63	11.97	12.32	12.58	13.13	13.25

Intervention	participants (Mean)
	CSC1/Day 1 (n= 543, 246)	CSC2/Day 1 (n= 33, 130)	CSC3/Day 1 (n= 23, 144)	CSC4/Day 1 (n= 279, 113)
Control	10.2	5.5	5.8	5.1
Intervention	9.5	0.6	0.4	4.8

Intervention	participants (Mean)
	CSC1/ day 1 (n= 2428, 1153)	CSC2/ day 1 (n= 237, 833)	CSC3/ day 1 (n= 171, 741)	CSC4/ day 1 (n= 2023, 815)
Control	47.5	35.7	32.2	37.8
Intervention	42.8	4.1	2.8	34.4

Intervention	participants (Number)
	1 SMRC5000	2 SMRC5000	3 SMRC5000	>3 SMRC5000
Control	136	38	12	5
Intervention	413	96	34	17